EP0983354A2 - Neurotrophen faktor rezeptoren - Google Patents
Neurotrophen faktor rezeptorenInfo
- Publication number
- EP0983354A2 EP0983354A2 EP98918805A EP98918805A EP0983354A2 EP 0983354 A2 EP0983354 A2 EP 0983354A2 EP 98918805 A EP98918805 A EP 98918805A EP 98918805 A EP98918805 A EP 98918805A EP 0983354 A2 EP0983354 A2 EP 0983354A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- gdnfr
- protein
- gdnf
- neurotrophic factor
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 title claims description 57
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 title claims description 57
- 210000004027 cell Anatomy 0.000 claims abstract description 429
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims abstract description 401
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims abstract description 401
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 117
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 92
- 102100033423 GDNF family receptor alpha-1 Human genes 0.000 claims abstract description 33
- 101000997961 Homo sapiens GDNF family receptor alpha-1 Proteins 0.000 claims abstract description 33
- 108010025020 Nerve Growth Factor Proteins 0.000 claims abstract description 27
- 102000007072 Nerve Growth Factors Human genes 0.000 claims abstract description 25
- 230000001086 cytosolic effect Effects 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 196
- 102000004169 proteins and genes Human genes 0.000 claims description 141
- 238000000034 method Methods 0.000 claims description 117
- 108010015406 Neurturin Proteins 0.000 claims description 93
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 89
- 241000282414 Homo sapiens Species 0.000 claims description 87
- 230000014509 gene expression Effects 0.000 claims description 87
- 239000013598 vector Substances 0.000 claims description 66
- 230000000694 effects Effects 0.000 claims description 49
- 238000004519 manufacturing process Methods 0.000 claims description 33
- 239000003446 ligand Substances 0.000 claims description 30
- 238000003556 assay Methods 0.000 claims description 28
- 210000002569 neuron Anatomy 0.000 claims description 28
- 239000003900 neurotrophic factor Substances 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 claims description 20
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 19
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 19
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 claims description 19
- 230000000295 complement effect Effects 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 230000026731 phosphorylation Effects 0.000 claims description 18
- 238000006366 phosphorylation reaction Methods 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000003321 amplification Effects 0.000 claims description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 210000004962 mammalian cell Anatomy 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 13
- 230000036755 cellular response Effects 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 230000000536 complexating effect Effects 0.000 claims description 12
- 238000002513 implantation Methods 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 8
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 8
- 208000028389 Nerve injury Diseases 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 7
- 230000008764 nerve damage Effects 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 230000001627 detrimental effect Effects 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 108020001756 ligand binding domains Proteins 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 101100456896 Drosophila melanogaster metl gene Proteins 0.000 claims 3
- 102100021584 Neurturin Human genes 0.000 claims 3
- 230000003053 immunization Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 119
- 108020003175 receptors Proteins 0.000 abstract description 119
- 108020004999 messenger RNA Proteins 0.000 abstract description 30
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract description 22
- 102000039446 nucleic acids Human genes 0.000 abstract description 22
- 108020004707 nucleic acids Proteins 0.000 abstract description 22
- 230000011664 signaling Effects 0.000 abstract description 19
- 230000004071 biological effect Effects 0.000 abstract description 17
- 238000010367 cloning Methods 0.000 abstract description 16
- 230000002209 hydrophobic effect Effects 0.000 abstract description 14
- 230000001537 neural effect Effects 0.000 abstract description 12
- 210000003169 central nervous system Anatomy 0.000 abstract description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 11
- 210000000170 cell membrane Anatomy 0.000 abstract description 9
- 210000004899 c-terminal region Anatomy 0.000 abstract description 8
- 210000000653 nervous system Anatomy 0.000 abstract description 7
- 210000001428 peripheral nervous system Anatomy 0.000 abstract description 6
- 238000012512 characterization method Methods 0.000 abstract description 5
- 230000003389 potentiating effect Effects 0.000 abstract description 5
- 238000009826 distribution Methods 0.000 abstract description 3
- 108090000722 Glial cell line-derived neurotrophic factor receptors Proteins 0.000 description 381
- 102000004216 Glial cell line-derived neurotrophic factor receptors Human genes 0.000 description 369
- 239000000047 product Substances 0.000 description 123
- 235000018102 proteins Nutrition 0.000 description 119
- 101150077555 Ret gene Proteins 0.000 description 110
- 230000027455 binding Effects 0.000 description 104
- 102000001839 Neurturin Human genes 0.000 description 90
- 108020004414 DNA Proteins 0.000 description 75
- 239000002299 complementary DNA Substances 0.000 description 65
- 241000700159 Rattus Species 0.000 description 63
- 239000000203 mixture Substances 0.000 description 49
- 229920001223 polyethylene glycol Polymers 0.000 description 47
- 239000002202 Polyethylene glycol Substances 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 42
- 239000000523 sample Substances 0.000 description 42
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 229940024606 amino acid Drugs 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 39
- 239000012634 fragment Substances 0.000 description 37
- 229920000642 polymer Polymers 0.000 description 37
- 125000000539 amino acid group Chemical group 0.000 description 35
- 238000011282 treatment Methods 0.000 description 35
- 230000035578 autophosphorylation Effects 0.000 description 34
- 241000894007 species Species 0.000 description 31
- 238000006467 substitution reaction Methods 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- 102000006486 Phosphoinositide Phospholipase C Human genes 0.000 description 24
- 108010044302 Phosphoinositide phospholipase C Proteins 0.000 description 24
- 239000011534 wash buffer Substances 0.000 description 24
- 238000012217 deletion Methods 0.000 description 23
- 230000037430 deletion Effects 0.000 description 23
- 238000009396 hybridization Methods 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 23
- 238000007792 addition Methods 0.000 description 22
- 210000002161 motor neuron Anatomy 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 239000013604 expression vector Substances 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 230000008569 process Effects 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 239000013615 primer Substances 0.000 description 18
- 238000001890 transfection Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000013595 glycosylation Effects 0.000 description 16
- 238000006206 glycosylation reaction Methods 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 16
- 108091008695 photoreceptors Proteins 0.000 description 16
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 230000006320 pegylation Effects 0.000 description 15
- 230000019491 signal transduction Effects 0.000 description 15
- 210000000278 spinal cord Anatomy 0.000 description 15
- 229920003169 water-soluble polymer Polymers 0.000 description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 239000012148 binding buffer Substances 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 238000001212 derivatisation Methods 0.000 description 13
- 210000005064 dopaminergic neuron Anatomy 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 210000000608 photoreceptor cell Anatomy 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 108091035707 Consensus sequence Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000004132 cross linking Methods 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 108091008551 RET receptors Proteins 0.000 description 10
- 239000003636 conditioned culture medium Substances 0.000 description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 238000005932 reductive alkylation reaction Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000005917 acylation reaction Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000003623 enhancer Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 8
- 238000000636 Northern blotting Methods 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 230000007850 degeneration Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 210000003594 spinal ganglia Anatomy 0.000 description 8
- 210000002222 superior cervical ganglion Anatomy 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 239000012133 immunoprecipitate Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 102000003916 Arrestin Human genes 0.000 description 6
- 108090000328 Arrestin Proteins 0.000 description 6
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 6
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 6
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 6
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108091060211 Expressed sequence tag Proteins 0.000 description 6
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 239000006137 Luria-Bertani broth Substances 0.000 description 6
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 6
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 102000004419 dihydrofolate reductase Human genes 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000028436 dopamine uptake Effects 0.000 description 6
- 238000001400 expression cloning Methods 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 230000009871 nonspecific binding Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- 210000001044 sensory neuron Anatomy 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 208000004592 Hirschsprung disease Diseases 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 108010055896 polyornithine Proteins 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 210000003523 substantia nigra Anatomy 0.000 description 5
- 230000002889 sympathetic effect Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 230000010474 transient expression Effects 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000010382 chemical cross-linking Methods 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920002714 polyornithine Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010010539 Congenital megacolon Diseases 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- -1 PCR Substances 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 210000000105 enteric nervous system Anatomy 0.000 description 3
- 210000005216 enteric neuron Anatomy 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 210000002241 neurite Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000002620 ureteric effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000007900 DNA-DNA hybridization Methods 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000016979 Other receptors Human genes 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108091006006 PEGylated Proteins Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 101000997827 Rattus norvegicus Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 201000003604 Renal agenesis Diseases 0.000 description 2
- 206010064655 Renal aplasia Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000004002 dopaminergic cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000014726 immortalization of host cell Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960000554 metrizamide Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 2
- 230000007441 retrograde transport Effects 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000002965 wolffian duct Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- FQERLIOIVXPZKH-UHFFFAOYSA-N 1,2,4-trioxane Chemical compound C1COOCO1 FQERLIOIVXPZKH-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- JSLGXODUIAFWCF-WDSKDSINSA-N Arg-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O JSLGXODUIAFWCF-WDSKDSINSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- RJUHZPRQRQLCFL-IMJSIDKUSA-N Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O RJUHZPRQRQLCFL-IMJSIDKUSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000038778 CNTF family Human genes 0.000 description 1
- 108091064557 CNTF family Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100024495 Cdc42 effector protein 4 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102000003967 Fibroblast growth factor 5 Human genes 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000762421 Homo sapiens Cdc42 effector protein 4 Proteins 0.000 description 1
- 101000957426 Homo sapiens Centrosomal protein of 135 kDa Proteins 0.000 description 1
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 101001108441 Homo sapiens Neurturin Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 108090000095 Neurotrophin-6 Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- 101710083778 Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- WVMHLYQJPRXKLC-UHFFFAOYSA-N borane;n,n-dimethylmethanamine Chemical compound B.CN(C)C WVMHLYQJPRXKLC-UHFFFAOYSA-N 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000008923 dopaminergic innervation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150082979 gdnf gene Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 108010067006 heat stable toxin (E coli) Proteins 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000052654 human GDNF Human genes 0.000 description 1
- 102000052667 human NRTN Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000029795 kidney development Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000000982 limb bud Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000003982 neuronal uptake Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 210000000584 nodose ganglion Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108010041634 preprotachykinin Proteins 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010006908 signal sequence receptor Proteins 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to receptors for neurotrophic factors.
- the invention relates to receptors for glial cell line-derived neurotrophic factor (GDNF) and neurturin and provides nucleic acid and amino acid sequences encoding the receptors.
- GDNF glial cell line-derived neurotrophic factor
- the present invention also relates to therapeutic techniques for the treatment of neurotrophic factors-responsive conditions.
- Glial Cell line-Derived Neurotrophic Factor Glial cell line-derived neurotrophic factor (GDNF) was initially isolated and cloned from rat B49 cells as a potent neurotrophic factor that enhances survival of midbrain dopaminergic neurons (Lin et al., Science, 260, 1130-1132, 1993). Recent studies have indicated that this molecule exhibits a variety of other biological activities, having effects on several types of neurons from both the central and peripheral nervous systems.
- GDNF central nervous system
- GDNF nigral dopaminergic neurons from axotomy-induced (Kearns and Gash, Brain Research, 672, 104-111, 1995; Beck et al., Nature, 373, 339-341, 1995) or neurotoxin-induced degeneration (Sauer et al., Proceedings Of The National Academy Of Sciences U.S.A., 92, 8935-8939, 1995; Tomac et al., Nature, 373, 335-339, 1995).
- local administration of GDNF has been shown to induce sprouting from dopaminergic neurons, increase levels of dopamine, noradrenaline, and serotonin, and improve motor behavior (Tomac et al, 1995 supra).
- GDNF has been reported to be a potential trophic factor for brain noradrenergic neurons and Purkinje cells. Grafting of fibroblasts ectopically expressing GDNF prevented 6-hydroxydopamine-induced degeneration and promoted the phenotype of adult noradrenergic neurons in vivo (Arenas et al., Neuron, 15, 1465-1473, 1995), while exogeneously applied GDNF effectively promoted survival and morphological differentiation of embryonic Purkinje cells in vitro (Mount et al., Proceedings Of The National Academy Of Sciences U.S.A., 92, 9092-9096, 1995).
- GDNF has been shown to promote the survival of neurons in nodose, ciliary, and sympathetic ganglia, as well as small populations of embryonic sensory neurons in dorsal root ganglia (DRG) and trigeminal ganglia (Trupp et al., Journal Of Cell Biology, 130, 137-148, 1995; Ebendal et al., Journal Of Neuroscience Research, 40, 276-284, 1995; Oppenheim et al, 1995 supra; Yan et al, 1995 supra; Henderson et al., 1994 supra).
- GDNF has also been reported to enhance the expression of vasoactive intestinal peptide and preprotachykinin-A mRNA in cultured superior cervical ganglion (SCG) neurons, and thus effects the phenotype of SCG neurons and induces bundle-like sprouting (Trupp et al., 1995 supra). Expression of GDNF has been observed in a number of different cell types and structures of the nervous system.
- GDNF mRNA expression has been observed by reverse transcriptase polymerase chain reaction (RT-PCR) in both developing and adult rat striatum, the major target of nigral dopaminergic innervation, and widely in other regions, including hippocampus, cortex, thalamus, septum, cerebellum, spinal cord, and medulla oblongata (Arenas et al., supra 1995; Poulsen et al., Neuron, 13, 1245-1252, 1994; Springer et al., Experimental Neurology, 127, 167-170, 1994; Stroemberg et al, Experimental Neurology, 124, 401-412, 1993; Schaar et al., Experimental Neurology, 124, 368-371, 1993).
- RT-PCR reverse transcriptase polymerase chain reaction
- GDNF transcripts have also been detected in striatum, with highest level in the caudate and lower levels in the putamen. Detectable levels are also found in hippocampus, cortex, and spinal cord, but not in cerebellum (Schaar et al., Experimental Neurology, 130, 387-393, 1994; Springer et al, 1994 supra).
- GDNF mRNA expression has been reported in DRG and SCG of postnatal day 1 rats, sciatic nerve, and primary cultures of neonatal Schwann cells (Trupp et al., 1995 supra; Hoffer et al., Neuroscience Letters, 182, 107- 111 , 1994; Henderson et al., 1994 supra; Springer et al, 1994 supra).
- recent studies have shown that GDNF transcripts are also widely expressed in peripheral non- neuronal organs, including postnatal testis and kidney, embryonic whisker pad, stomach, and skin.
- GDNF protein product includes biologically active synthetic or recombinant GDNF proteins and analogs, as well as chemically modified derivatives thereof.
- GDNF analogs include deletion variants such as truncated GDNF proteins, as well as insertion and substitution variants of GDNF. Also included are GDNF proteins that are substantially homologous to the human GDNF protein.
- GDNF therapy is helpful in the treatment of nerve damage caused by conditions that compromise the survival and/or proper function of one or more types of nerve cells.
- nerve damage may occur from a wide variety of different causes.
- Nerve damage may occur to one or more types of nerve cells by: (1) physical injury, which causes the degeneration of the axonal processes and/or nerve cell bodies near the site of injury; (2) temporary or permanent cessation of blood flow to parts of the nervous system, as in stroke; (3) intentional or accidental exposure to neurotoxins, such as chemotherapeutic agents (e.g., cisplatinum) for the treatment of cancer or dideoxycytidine (ddC) for the treatment of AIDS; (4) chronic metabolic diseases, such as diabetes or renal dysfunction; or (5) neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS), which result from the degeneration of specific neuronal populations.
- chemotherapeutic agents e.g., cisplatinum
- ddC
- GDNF therapy is particularly helpful in the treatment of neurodegenerative conditions such as the degeneration of the dopaminergic neurons of the substantia nigra in Parkinson's disease.
- the only current treatments for Parkinson's disease are palliative, aiming at increasing dopamine levels in the striatum.
- the expected impact of GDNF therapy is not simply to produce an increase in the dopaminergic neurotransmission at the dopaminergic nerve terminals in the striatum (which will result in a relief of the symptoms), but also to slow down, or even stop, the progression of the degenerative processes and to repair the damaged nigrostriatal pathway and restore its function.
- GDNF may also be used in treating other forms of damage to or improper function of dopaminergic nerve cells in human patients.
- Receptors A number of receptors which mediate binding and response to protein factors have been characterized and molecularly cloned, including receptors for insulin, platelet derived growth factor, epidermal growth factor and its relatives, the fibroblast growth factors, various interleukins, hematopoietic growth factors and ciliary neurotrophic factor (U.S. 5,426,177).
- receptors can bind to multiple (related) growth factors, while in other cases the same factor can bind and activate multiple (related) receptors (e.g., Lupu et al., Science, 249:1552-1555, 1990; Dionne et al., EMBO J., 9:2685-2692, 1990; Miki et al., Science, 251 :72-75, 1991).
- Most receptors can broadly be characterized as having an extracellular portion or domain responsible for specifically binding a protein factor, a transmembrane domain which spans the cell membrane, and an intracellular domain that is often involved in initiating signal transduction upon binding of the protein factor to the receptor's extracellular portion.
- receptors Although many receptors are comprised of a single polypeptide chain, other receptors apparently require two or more separate subunits in order to bind to their protein factor with high-affinity and to allow functional response following binding (e.g., Hempstead et al., Science, 243:373-375, 1989; Hibi et al., Cell, 63:1149-1157, 1990).
- the extracellular and intracellular portions of a given receptor may share common structural motifs with the corresponding regions of other receptors, suggesting evolutionary and functional relationships between different receptors. These relationships can often be quite distant and may simply reflect the repeated use of certain general domain structures. For example, a variety of different receptors that bind unrelated factors make use of "immunoglobulin" domains in their extracellular portions, while other receptors utilize "cytokine receptor” domains in their factor-binding regions (e.g., Akira et al, The FASEB J., 4:2860-2867, 1990).
- a large number of receptors with distinct extracellular binding domains (which thus bind different factors) contain related intracytoplasmic domains encoding tyrosine- specific protein kinases that are activated in response to factor binding (e.g., Ullrich and Schlessinger, Cell, 61:203-212, 1990).
- factor binding e.g., Ullrich and Schlessinger, Cell, 61:203-212, 1990.
- factor- binding e.g., Ullrich and Schlessinger, Cell, 61:203-212, 1990.
- the mechanisms by which factor- binding "activates" the signal transduction process is poorly understood, even in the case of receptor tyrosine kinases.
- the intracellular domain encodes a domain of unknown function or in which the binding component associates with a second protein of unknown function (e.g., Hibi et al., Cell, 63:1149-1157, 1990)
- activation of signal transduction is not well characterized.
- GDNF striatum injected [125r]_ ⁇ a b e ⁇ ec ⁇ GDNF can be retrogradely transported by dopaminergic neurons in the substantia nigra (Tomac et al., Proceedings Of The National Academy Of Sciences Of The United States Of America. 92, 8274-8278, 1995; Yan et al., 1995 supra). Retrograde transport of [125J]_QDNF by spinal cord motor neurons, DRG sensory neurons and neurons in the B layer of retina ganglia was also been observed.
- GDNF on motor neurons in a 5 to 10 fM range, is even lower than that on dopaminergic neurons (Henderson et al., 1994 supra).
- GDNF GDNF activates signal transduction to exert its affects on cells
- the identification of a protein receptor for GDNF would provide powerful applications in diagnostic uses, for example, as an aid in determining if individuals would benefit from GDNF protein therapy.
- the protein receptor for GDNF could be a key component in an assay for identifying additional molecules which bind to the receptor and result in desired biological activity.
- the present invention provides nucleic acid sequences which encode neurotrophic factor receptor proteins having amino acid sequences as depicted in the Figures as well as biologically equivalent analogs.
- the neurotrophic factor receptor protein and protein products of the present invention are designated herein as glial cell line-derived neurotrophic factor receptor (GDNFR) protein and protein products.
- GDNFR glial cell line-derived neurotrophic factor receptor
- Particular receptor proteins refered to herein include GDNFR- ⁇ , and glial cell line- derived neurotrophic factor receptor- ⁇ -related receptor proteins 2 and 3 (GRR2 and GRR3).
- GDNFR glial cell line-derived neurotrophic factor receptor
- GRR2 and GRR3 glial cell line- derived neurotrophic factor receptor- ⁇ -related receptor proteins 2 and 3
- GDNFR protein products are typically provided as a soluble receptor protein and in a substantially purified form.
- the present invention provides for the production of GDNFR protein products by recombinant genetic engineering techniques.
- the GDNFR proteins are synthesized by chemical techniques, or a combination of the recombinant and chemical techniques.
- the GDNFR proteins may be made in glycosylated or non-glycosylated forms.
- Derivatives of GDNFR protein typically involve attaching the GDNFR protein to a water soluble polymer.
- the GDNFR protein may be conjugated to one or more polyethylene glycol molecules to decrease the precipitation of the GDNFR protein product in an aqueous environment.
- Yet another aspect of the present invention includes the various polynucleotides encoding GDNFR proteins.
- nucleic acid sequences are used in the expression of GDNFR in a eukaryotic or prokaryotic host cell, wherein the expression product or a derivative thereof is characterized by the ability to bind to GDNF and thereby form a complex capable of mediating GDNF activity, such as increasing dopamine uptake by dopaminergic cells.
- the polynucleotides may also be used in cell therapy or gene therapy applications. Suitable nucleic acid sequences include those specifically depicted in the Figures as well as degenerate sequences, naturally occurring allelic variations and modified sequences based on the present invention.
- nucleic acid sequences include sequences encoding a neurotrophic factor receptor protein comprising an amino acid sequence as depicted in the Figures capable of complexing with glial cell line-derived neurotrophic factor (GDNF) and/or neurturin and mediating cell response to GDNF and/or neurturin, and biologically equivalent analogs thereof.
- Such sequences include: (a) a sequence set forth in Figure 1 (SEQ ID NO. 1) comprising nucleotides encoding Met* through S er 465 or Figure 3 (SEQ ID NO.
- GDNFR- ⁇ neurotrophic factor receptor
- GDNF glial cell line-derived neurotrophic factor
- GRR2 and GRR3 glial cell line-derived neurotrophic factor
- a nucleic acid sequence which but for the degeneracy of the genetic code would hybridize to a complementary sequence of (a) and (2) encodes an amino acid sequence with GDNFR activity.
- vectors such nucleic acid sequences wherein the sequences typically are operatively linked to one or more operational elements capable of effecting the amplification or expression of the nucleic acid sequence.
- Host cells containing such vectors are also contemplated.
- the host cell is selected from mammalian cells and bacterial cells, such as a COS-7 cell or E. coli, respectively.
- a further aspect of the present invention involves vectors containing the polynucleotides encoding GDNFR proteins operatively linked to amplification and/or expression control sequences.
- Both prokaryotic and eukaryotic host cells may be stably transformed or transfected with such vectors to express GDNFR proteins.
- the present invention further includes the recombinant production of a GDNFR protein wherein such transformed or transfected host cells are grown in a suitable nutrient medium, and the GDNFR protein expressed by the cells is, optionally, isolated from the host cells and/or the nutrient medium.
- the present invention further includes the use of polynucleotides encoding GDNFR protein and vectors containing such polynucleotides in gene therapy or cell therapy.
- the host cell may also be selected for its suitability to human implantation, wherein the implanted cell expresses and secretes a neurotrophic factor receptor of the present invention.
- the host cell also may be enclosed in a semipermeable membrane suitable for human implantation.
- the host cell may be transformed or transfected ex vivo.
- An exemplary device for treating nerve damage involves: (a) a semipermeable membrane suitable for implantation; and (b) cells encapsulated within the membrane, wherein the cells express and secrete a neurotrophic factor receptor as disclosed herein.
- the membrane is selected from a material that is permeable to the neurotrophic factor receptor protein but impermeable to materials detrimental to the encapsulated cells.
- An exemplary method involves: (a) culturing a host cell containing a nucleic acid sequence encoding a GDNFR protein of the present invention, such as an amino acid sequence depicted in the Figures capable of complexing with glial cell line-derived neurotrophic factor and/or neurturin and mediating cell response to GDNF and/or neurturin, or biologically equivalent analogs thereof; (b) maintaining said host cell under conditions suitable for the expression of said neurotrophic factor receptor by said host cell; and (c) optionally, isolating said neurotrophic factor receptor expressed by said host cell.
- the host cell may be a prokaryotic cell or a eukaryotic cell. If bacterial expression is involved, the method may further include the step of refolding the neurotrophic factor receptor.
- the present invention includes an isolated and purified protein comprising an amino acid sequence as depicted in the Figures capable of complexing with glial cell line-derived neurotrophic factor and/or neurturin and mediating cell response to GDNF and/or neurturin, and biologically equivalent analogs thereof.
- Exemplary analogs include, but are not limited to, proteins comprising the amino acid sequence Ser 18 through Pro 446 , Asp 25 through Leu 447 and Cys 29 through Cys 442 as depicted in Figure 2 (SEQ ID NO:2) as well as proteins comprising the amino acid sequence Met ⁇ 7 through Pro 449 and Cys 29 through Cys 44 ⁇ as depicted in Figure 4 (SEQ ID NO:4).
- the proteins of the present invention may be glycosylated or non- glycosylated and may be produced by recombinant technology or chemical synthesis.
- the present invention further includes nucleic acid sequences encoding a receptor protein comprising such amino acid sequences.
- compositions comprising a GDNFR protein of the present invention in combination with a pharmaceutically acceptable carrier.
- a variety of other formulation materials may be used to facilitate manufacture, storage, handling, delivery and/or efficacy.
- Another aspect of the present invention includes the therapeutic use of GDNFR genes and proteins.
- a circulating or soluble GDNFR protein product may be used alone or in conjunction with GDNF and/or neurturin in treating disease of or injury to the nervous system by enhancing the activity of transmembrane signaling of GDNF and/or neurturin.
- the proteins and pharmaceutical compositions of the present invention may be used in treating improperly functioning dopaminergic nerve cells, Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis.
- a recombinant GDNFR gene may be inserted in the cells of tissues which would benefit from increased sensitivity to GDNF or neurturin, such as motor neurons in patients suffering from amyotrophic lateral sclerosis.
- GDNFR may be used to block GDNF or neurturin activity in cases where the GDNF or neurturin activity is thought to be detrimental.
- the GDNFR protein may be used to verify that observed effects of GDNF or neurturin are due to the GDNFR protein.
- GDNFR probes may be used to identify cells and tissues which are responsive to GDNF or neurturin in normal or diseased states. Alternatively, the probes may be used to detect an aberrancy of GDNFR protein expression in a patient suffering from a GDNF- or neurturin-related disorder.
- GDNFR probes including nucleic acid as well as antibody probes, may be used to identify GDNFR-related molecules. For example, the present invention provides for such molecules which form a complex with GDNFR protein and thereby participate in GDNFR protein function.
- the present invention provides for receptor molecules which are homologous or cross-reactive antigenically, but not identical to GDNFR- ⁇ , GRR2 or GRR3, including consensus sequence molecules as depicted in the Figures.
- the present invention also provides for the development of both binding and functional assays for GDNF or neurturin based on the receptor.
- assay systems for detecting GDNF activity may involve cells which express high levels of GDNFR- ⁇ , and which are therefore extremely sensitive to even very low concentrations of GDNF or GDNF-like molecules. Similar assays may involve neurturin and GRR2.
- soluble GDNFR may be used to bind or detect the presence of GDNF or GDNF-like molecules.
- the present invention provides for experimental model systems for studying the physiological role of GDNF or neurturin.
- Such systems include assays involving anti-GDNFR antibodies or oligonucleotide probes as well as animal models, such as transgenic animals which express high levels of GDNFR and therefore are hypersensitive to GDNF and/or neurturin or animals derived using embryonic stem cell technology in which the endogenous GDNFR genes were deleted from the genome.
- An anti-GDNFR antibody will binds a peptide portion of the neurotrophic factor receptor proteins.
- Antibodies include monoclonal and polyclonal antibodies.
- immunological tags for which antibodies already exist may be attached to the GDNFR protein to aid in detection. Such tags include but are not limited to Flag (IBI/Eastman Kodak) and myc sequences. Other tag sequences such as polyhistidine have also been used for detection and purification on metal chelating columns.
- GDNFRs to identify ligands which activate receptors as described in the following detailed description and examples. Proteins as well as small molecule neurotrophic factor mimetics may be identified and studied following the binding studies described herein.
- Figure 1 depicts a nucleic acid sequence (SEQ ID NO:l) encoding human glial cell line-derived neurotrophic factor receptor (GDNFR- ⁇ ).
- the amino acid sequence of the full length GDNFR protein is encoded by nucleic acids 540 to 1934.
- Figure 2 depicts the amino acid sequence (SEQ ID NO:2) of the full length human GDNFR- ⁇ protein.
- Figure 3 depicts a nucleic acid sequence (SEQ ID NO:3) encoding rat GDNFR- ⁇ .
- the amino acid sequence of the full length GDNFR- ⁇ protein is encoded by nucleic acids 302 to 1705.
- Figure 4 depicts the amino acid sequence (SEQ ID NO:4) of the full length rat GDNFR- ⁇ protein
- Figure 5 depicts the alignment and comparison of portions of GDNFR- ⁇ cDNA sequences produced in various clones as well as the consensus sequence for human GDNFR- ⁇ .
- Figure 6 depicts the identification of Neuro-2A derived cell lines expressing GDNFR- ⁇ .
- Figure 7 A and 7B depict the results of the equilibrium binding of [ 125 I]GDNF to cells expressing GDNFR- ⁇ .
- Figure 8 depicts the results of the chemical cross-linking of to GDNFR- ⁇ and Ret Expressed in cells expressing GDNFR- ⁇ .
- Figure 9 depicts the results of the induction of c-Ret autophosphorylation by
- Figure 10 depicts the results of the induction of c-Ret autophosphorylation by GDNF and soluble GDNFR- ⁇ .
- Figure 11 depicts the results of the blocking of c-Ret autophosphorylation by a Ret-Fc fusion protein.
- Figure 12 depicts the results of the induction of c-Ret autophosphorylation by GDNF in motor neurons.
- Figure 13 depicts a model for GDNF signaling mediated by GDNFR- ⁇ and Ret.
- Figure 14 depicts a nucleic acid sequence (SEQ ID NO: ) encoding human glial cell line-derived neurotrophic factor receptor- ⁇ -related protein 2 (GRR2).
- SEQ ID NO: human glial cell line-derived neurotrophic factor receptor- ⁇ -related protein 2
- the amino acid sequence of the full length GRR2 protein is encoded by nucleic acids 1585 to 2989.
- Figure 15 depicts a nucleic acid sequence (SEQ ID NO: ) encoding human glial cell line-derived neurotrophic factor receptor- ⁇ -related protein 3 (GRR3).
- SEQ ID NO: human glial cell line-derived neurotrophic factor receptor- ⁇ -related protein 3
- Figure 16 depicts a nucleic acid sequence (SEQ ID NO: ) encoding rat glial cell line-derived neurotrophic factor receptor- ⁇ -related protein 2 (rat GRR2).
- Figure 17 depicts a nucleic acid sequence (SEQ ID NO: ) encoding rat glial cell line-derived neurotrophic factor receptor- ⁇ -related protein 3 (rat GRR3).
- Figure 18 depicts the alignment and comparison of various human, rat and mouse GDNFR amino acid sequences.
- Figure 19 depicts the alignment and comparison of human, rat and mouse
- GDNFR- ⁇ GRR2 AND GRR3 amino acid sequences and an exemplary consensus GDNFR sequence.
- Figure 20 depicts the alignment and comparison of human and rat GDNFR- ⁇ and GRR2 peptide sequences.
- Figure 21 depicts the binding of neurturin and GDNF to LA-N-% and NGR-38 cells.
- LA-N-5 Panel A
- NGR-38 Panel B cells were incubated with 50 pM of either [ l25 I]NTN or [ l25 I]GDNF in the absence (light gray bars) or presence of unlabeled GDNF (dark gray bars) or neurturin (black bars) at 4°C for two hours.
- Figure 22 depicts the results of the chemical cross-linking of neurturin and GDNF to GDNFR- ⁇ and GRR2.
- Figure 23 depicts the results of neurturin induced ret autophosphorylation in NGR-38 cells.
- Figure 24 depicts the results of neurturin induced ret autophosphorylation in LA-N-5 cells.
- Figure 25 depicts the results of neurturin and GDNF induced MAP kinase activation in LA-N-5 and NGR-38 cells.
- Figure 26 depicts the amino acid sequences of GDNFR- ⁇ , GRR2 and GRR3 are aligned and a consensus sequence is shown above the three receptor sequences.
- Upper case letters in the consensus sequence indicate amino acids that are conserve in all three receptors, lower case letters indicate that two of the three receptors sh? that amino acid, and dots indicate all three receptors have a different amino ac ; j that position.
- Predicted signal peptide sequences are underlined in GDNFR- ⁇ • GRR3; no signal peptide is predicted for GRR2.
- the hydrophobic C-termina regions of all three putative receptors are underlined. Potential N-glycosyla are shown in boldface and sites conserved between two receptors are outlined by boxes.
- Glial cell line-derived neurotrophic factor is a potent neurotrophic factor which exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. It is a glycosylated, disulfide-linked dimer which is distantly related (less than 20% homology) to the transforming growth factor- ⁇ (TGF- ⁇ ) superfamily. GDNF's ability to enhance the survival of dopaminergic neurons and other neuron populations demonstrates its therapeutic potential for the treatment of Parkinson's disease as well as other forms of nerve damage or malfunction. The described biological activities of the neurturin neurotrophic factor
- neurturin may be useful in the treatment of diseases for which the use of GDNF may be indicated.
- the present invention is based upon the discovery of a high affinity receptor first found on the surface of cultured retinal cells from postnatal rats. These receptors possess an estimated GDNF binding affinity comparable to that of the receptors found in dopaminergic and motor neurons; midbrain dopaminergic neurons (Lin et al., 1993 supra; Sauer et al., 1995 supra; Kearns and Gash, 1995 supra; Beck et al., 1995 supra; Tomac et al., 1995a supra), facial and spinal cord motor neurons (Li et al., 1995 supra; Oppenheim et al, 1995 supra; Yan et al, 1995 supra; Zurn et al., 1994 supra; Henderson et al., 1994 supra).
- the receptor molecule has been named GDNF receptor-alpha (GDNFR- ⁇ ) since it is the first known component of a receptor system for GDNF.
- the present invention also provides the first description of the expression cloning and characterization of GDNFR- ⁇ protein.
- Cells modified to express the recombinant receptor bind GDNF with high affinity.
- Additional receptor proteins include glial cell line-derived neurotrophic factor receptor- ⁇ related receptor proteins 2 and 3 (GRR2 and GRR3). Using a dopamine uptake assay and [1 2 ⁇ I]-GDNF binding on cultured cells, high affinity receptors to GDNF were detected on the surface of rat photoreceptor cells.
- the nucleic acid sequence for GDNFR- ⁇ encodes a protein of 468 amino acids with 31 cysteine residues and three potential N-glycosylation sites.
- a nucleic acid sequence from the rat cDNA clone was used to isolate its human homolog which was found to be nearly identical to the rat receptor at the amino acid level.
- the human GDNFR- ⁇ cDNA sequence encodes a protein of 465 amino acids with the positions of all cysteine residues and potential N-glycosylation sites conserved relative to the rat receptor. This high degree of primary sequence conservation indicated an important role for this receptor in the biological function of GDNF.
- receptors have three main domains: an extracellular or cell surface domain responsible for specifically binding a protein factor; a transmembrane domain which spans the cell's membrane; and an intracellular or cytoplasmic domain that is typically involved in initiating signal transduction when a protein factor binds to the extracellular domain.
- GDNFR- ⁇ is unrelated in sequence or structural characteristics to any known protein (such as the consensus sequences found in either receptor kinases or cytokine receptors), lacks a cytoplasmic domain, lacks the C-terminal charged residues characteristic of a transmembrane domain and is anchored to the cell membrane by glycosyl-phosphatidylinositol (GPI) linkage, as described in greater detail below.
- GPI glycosyl-phosphatidylinositol
- GDNFR- ⁇ lacks a cytoplasmic domain, it was thought that this receptor must act in conjunction with one or more accessory molecules which play a role in transmembrane signaling. It was then discovered that transgenic mice which lack the gene for GDNF die and have no kidneys. Transgenic mice which lack the gene for c-ret proto-oncogene (Schuchardt, et al., Nature, 367, 380-383, 1994) were found to have a similar phenotype. The c-ret proto-oncogene encodes a receptor tyrosine kinase (RTK) whose normal function had not yet been determined.
- RTK receptor tyrosine kinase
- RTKs have a similar topology: they possess an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic segment containing the catalytic protein- tyrosine kinase domain. Binding of a ligand leads to the activation of the kinase domain and phosphorylation of specific substrates in the cell that mediate intracellular signaling.
- the present invention involves the discovery that a soluble form of GDNFR- ⁇ may be used to mediate the binding of GDNF to the c-ret proto- oncogene and thereby elicit a cellular response to GDNF as well as modify its cell- type specificity.
- receptor alpha components Similar species, called “receptor alpha” components, provide ligand binding specificity but do not have the capacity to transduce signal on their own. Such components are found in the ciliary neurotrophic factor (CNTF) and interleukin-6 (IL-6) receptor systems. Like GDNFR- ⁇ , and in contrast to IL-6 receptor, CNTF receptor binds its ligand with high affinity, has a hydrophobic C-terminus, no cytoplasmic domain, and is anchored to the cell membrane by GPI linkage (Davis et al., 1991). In order to mediate signal transduction, CNTF binds first to CNTF receptor, creating a complex which is able to bind gpl30.
- CNTF ciliary neurotrophic factor
- IL-6 interleukin-6
- This inactive complex then binds to LIF receptor to form the active signaling complex (Davis, et al., Science, 260, 1805-1807, 1993).
- CNTF receptor the ligand specific binding component
- CNTF receptor the ligand specific binding component
- the GDNFR protein may be anchored to a cell surface, or it may be provided in a soluble form. In either case, the GDNFR protein forms a ligand complex with GDNF and/or neurturin, and the ligand complex binds to cell surface receptor to effectuate intracellular signaling.
- a soluble form of GDNFR protein may be used to potentiate the action of a neurotrophic factor that binds thereto and/or modify its cell-type specificity.
- the GDNFR proteins are unrelated to previously known receptors. There are no apparent matches in the GenBank and Washington University-Merck databases for related sequences.
- An expressed sequence tag (EST) found in the Washington University-Merck EST database shows 75% homology to a small portion of the coding region of GDNFR- ⁇ (approximately 340 nucleotides of the 521 nucleotides of sequence generated from the 5' end of the clone).
- This clone (GenBank accession #H12981) was isolated from an oligo-dT primed human infant brain library and cloned directionally into the Lafmid BA vector (Hillier, L. et al, unpublished data).
- the 3' end of the #H 12981 clone has been sequenced, but it exhibits no homology to any part of GDNFR- ⁇ .
- the present invention enables the cloning of a GDNFR protein by providing a method for selecting target cells which express GDNFR protein.
- the present invention further provides for the purification of GDNFR protein and the direct cloning of GDNFR-encoding DNA.
- the present description of the GDNFR nucleic acid and amino acid sequences provides the information needed to reproduce these entities as well as a variety of GDNFR analogs. With this information, GDNFR protein products may be isolated or generated by any means known to those skilled in the art. A variety of means for the recombinant or synthetic production of GDNFR protein are disclosed.
- GDNFR protein product includes biologically active purified natural, synthetic or recombinant GDNFR- ⁇ , GRR2 and GRR3
- GDNFR glial cell line derived neurotrophic factor receptors
- GDNFR protein GDNFR analogs
- GDNFR analogs i.e., GDNFR homologs and variants involving insertion, substitution and deletion variations, such as based on the consensus sequences depicted in the Figures
- chemically modified derivatives thereof GDNFR analogs are substantially homologous to the GDNFR amino acid sequences set forth in the Figures.
- biologically active means that the GDNFR protein product demonstrates high affinity binding to GDNF and/or neurturin and mediates or enhances GDNF-induced or neurturin-induced signal transduction. Using the present disclosure, it is well within the ability of those of ordinary skill in the art to determine whether a GDNFR protein analog has substantially the same biological activity as the GDNFR protein products set forth in the Figures.
- substantially homologous amino acid sequence refers to an amino acid sequence sharing a degree of “similarity" or homology to the GDNFR amino acid sequences set forth in the Figures such that the homologous sequence has a biological activity or function similar to that described for these GDNFR amino acid sequences. It will be appreciated by those skilled in the art, that a relatively large number of individual or grouped amino acid residues can be changed, positionally exchanged (e.g.s, reverse ordered or reordered) or deleted entirely in an amino acid sequence without affecting the three dimensional configuration or activity of the molecule. Such modifications are well within the ability of one skilled in the art following the present disclosure. The identification and means of providing such modified sequences are described in greater detail below.
- the degree of homology of a substantially homologous protein is equal to or in excess of 70% (i.e., a range of from 70% to 100% homology).
- a preferable "substantially homologous" GDNFR amino acid sequence may have a degree of homology greater than or equal to 70% of the amino acid sequences set forth for GDNFR- ⁇ , GRR2, GRR3 and consensus sequences thereof as depicted in the Figures. More preferably the degree of homology may be equal to or in excess of 80% or 85%. Even more preferably it is equal to or in excess of 90%, or most preferably it is equal to or in excess of 95%.
- the percentage of homology as described herein is calculated as the percentage of amino acid residues found in one protein sequence which align with identical or similar amino acid residues in the second protein sequence.
- the degree of sequence homology may be determined by optimally aligning the amino acid residues of the comparison molecule to those of a reference GDNFR polypeptide, such as depicted in the
- the percentage is determined by the number of aligned residues in the comparison polypeptide divided by the total number of residues in the comparison polypeptide. It is further contemplated that the GDNFR protein sequences of the present invention may be used to form a portion of a fusion protein or chimeric protein which has, at least in part, GDNFR protein activity. The alignment and homology of such a protein would be determined using that portion of the fusion protein or chimeric protein which is related to GDNFR protein activity.
- substantially homologous GDNFR proteins include the GDNFR proteins of other mammals (such as depicted in the Figures) which are expected to have a high degree of homology to the human GDNFR protein.
- the degree of homology between the rat and human GDNFR- ⁇ proteins disclosed herein is about 93%.
- Substantially homologous GDNFR proteins may be isolated from such mammals by virtue of cross-reactivity with antibodies to the GDNFR amino acid sequences depicted in the Figures. Alternatively, they may be expressed by nucleic acid sequences which are isolated through hybridization with the gene or with segments of the gene encoding the GDNFR proteins or which hybridize to a complementary sequence of the nucleic acid sequences illustrated in the Figures.
- the novel GDNFR protein products are typically isolated and purified to form GDNFR protein products which are substantially free of unwanted substances that would detract from the use of the present polypeptides for an intended purpose.
- preferred GDNFR protein products may be substantially free from the presence of other human (e.g., non-GDNFR) proteinaceous materials or pathological agents.
- the GDNFR protein products are about 80% free of other proteins which may be present due to the production technique used in the manufacture of the GDNFR protein product. More preferably, the GDNFR protein products are about 90% free of other proteins, particularly preferably, about 95% free of other proteins, and most preferably about >98% free of other proteins.
- the present invention furnishes the unique advantage of providing polynucleotide sequences for the manufacture of homogeneous GDNFR proteins.
- GDNFR variants are contemplated, including addition, deletion and substitution variants.
- a series of deletion variants may be made by removing one or more amino acid residues from the amino and/or carboxy termini of the GDNFR protein.
- the first amino acid residue of the GDNFR- ⁇ protein which might be involved in GDNF binding is Ser ⁇ °, as depicted in the full length amino acid sequence of human GDNFR- ⁇ in Figure 2 (SEQ ID NO:2).
- Amino acid residues Met 1 through Ser 18 are in the amino-terminal hydrophobic region that is likely to be part of a signal peptide sequence, and therefore, not be included in the mature form of the receptor protein.
- the last amino acid residue of the GDNFR- ⁇ protein which is likely to be necessary for GDNF binding is Ser 44o ⁇
- Amino acid residues Leu 447 through Ser 4 ⁇ are m the carboxy-terminal hydrophobic region that is involved in the GPI linkage of the protein to the cell surface.
- any or all of the residues from Met ⁇ through Ser 18 and/or Leu 447 through Ser 4 ⁇ may be removed from the protein without affecting GDNF binding to the GDNFR- ⁇ protein, thereby leaving a "core" sequence of Ala 19 through Pro 44 ⁇ .
- N-terminal truncations may include the removal of one or more amino acid residues up to and including Gly 24 .
- GDNFR- ⁇ truncation analogs also may include the deletion of one or more amino acid residues from either or both termini such that an amino acid sequence of Asp 2 * through Pro 44 " or Leu 447 forms the basis for a core molecule.
- Additional GDNFR- ⁇ analogs are contemplated as involving amino acid residues Ser 18 through Pro 449 as depicted in the GDNFR- ⁇ amino acid sequence of Figure 4 (SEQ ID NO:4) , i.e., deleting one or more amino acid residues from either or both termini involving the hydrophobic regions depicted as amino acid residues Met 1 through Ser 18 and/or Pro 449 through ⁇ er 468
- Similar analogs may be designed using the amino acid sequences for GRR2 and GRR3, as well as consensus sequences, as depicted in the Figures.
- one or more amino acid residues may be removed from either or both of the amino and carboxy termini of the GDNFR protein until the first and last cysteine residues in the full length sequence are reached. It is advantageous to retain the cysteine residues for the proper intramolecular binding of the GDNFR protein. As depicted in the full length amino acid sequence of human GDNFR- ⁇ in Figure 2 (SEQ ID NO:2), any or all of amino acid residues from Met 1 to Asp 28 may be removed from the amino terminal without removing the first cysteine residue which appears as Cys 29 .
- any or all of amino acid residues from Gly 44 ⁇ to Ser 4 " ⁇ may be removed from the carboxy terminal without removing the last cysteine residue which appears as Cys 442 .
- Other GDNFR- ⁇ analogs may be made using amino acid residues Cys 29 through Cys 44 ⁇ as depicted in the GDNFR- ⁇ amino acid sequence of Figure 4 (SEQ ID NO:4) , i.e., deleting all or part of the terminal regions depicted as amino acid residues Met 1 through Asp 28 and/or Ser 444 through Ser 4 " 8 . Similar analogs may be designed using the amino acid sequences for GRR2 and GRR3, as well as consensus sequences, as depicted in the Figures.
- these identified amino acid residues may be replaced, rather than deleted, without affecting the function of the GDNFR protein.
- these identified amino acid residues may be modified by intra-residue insertions or terminal additions without affecting the function of the GDNFR protein.
- a combination of one or more deletions, substitutions or additions may be made.
- the present GDNFR proteins or nucleic acids may be used for methods of treatment, or for methods of manufacturing medicaments for treatment.
- Such treatment includes conditions characterized by excessive production of GDNF or neurturin, wherein the present GDNFRs, particularly in soluble form, may be used to complex to and therefore inactivate such excessive GDNF or neurturin.
- This treatment may be accomplished by preparing a soluble receptor (e.g., use of the GDNF or neurturin binding domain) or by preparation of a population of cells containing such GDNFR, and transplanting such cells into the individual in need thereof.
- the present GDNFR protein products may also be used for treatment of those having defective GDNF and/or neurturin receptors.
- an individual may have an inadequate number of GDNF or neurturin receptors, and cells containing such receptors may be transplanted in order to increase the number of GDNF or neurturin receptors available to an individual.
- Such compositions may be used in conjunction with the delivery of GDNF or neurturin.
- GDNFR protein products may be used in the treatment of conditions responsive to the activation of the c-ret receptor tyrosine kinase.
- a further advantage to the novel compositions is the use of GDNFR to stabilize GDNF protein or neurturin pharmaceutical compositions.
- a GDNFR may be used to screen compounds for antagonist activity.
- additional uses include new assay systems, transgenic animals and antibody production.
- the present invention provides for assay systems in which GDNF or neurturin activity or activities similar to GDNF or neurturin activity resulting from exposure to a peptide or non-peptide compound may be detected by measuring an elicited physiological response in a cell or cell line which expresses the GDNFR molecules of the present invention.
- a physiological response may comprise any of the biological effects of GDNF or neurturin, including but not limited to, dopamine uptake, extension of neurites, increased cell survival or growth, as well as the transcriptional activation of certain nucleic acid sequences (e.g. promoter/enhancer elements as well as structural genes), GDNF-related processing, translation, or phosphorylation, and the induction of secondary processes in response to processes directly or indirectly induced by GDNF, to name but a few.
- nucleic acid sequences e.g. promoter/enhancer elements as well as structural genes
- GDNF-related processing e.g. promoter/enhancer elements as
- a model system may be created which may be used to study the effects of excess GDNF activity.
- the response of a cell to GDNF may be increased by engineering an increased number of suitable GDNFRs on the cells of the model system relative to cells which have not been so modified.
- a system may also be developed to selectively provide an increased number of such GDNFRs on cells which normally express GDNFRs.
- the GDNFR gene may be placed under the control of a suitable promoter sequence.
- GDNFR gene under the control of a constitutive and/or tissue specific promoter (including but not limited to the CNS neuron specific enolase, neurofilament, and tyrosine hydroxylase promoter), an inducible promoter (such as the metallothionein promoter), the UN activated promoter in the human immunodeficiency virus long terminal repeat (Naleri et al., 1988, Nature 333:78-81), or the CMV promoter (as contained in pCMX, infra) or a developmentally regulated promoter.
- a constitutive and/or tissue specific promoter including but not limited to the CNS neuron specific enolase, neurofilament, and tyrosine hydroxylase promoter
- an inducible promoter such as the metallothionein promoter
- the UN activated promoter in the human immunodeficiency virus long terminal repeat Naleri et al., 1988, Nature 333:78-81
- CMV promoter as contained in
- GDNF By increasing the number of cellular GDNFRs, the response to endogenous GDNF may be increased. If the model system contains little or no GDNF, GDNF may be added to the system. It may also be desirable to add additional GDNF to the model system in order to evaluate the effects of excess GDNF activity. Over expressing GDNF (or secreted GDNF) may be one method for studying the effects of elevated levels of GDNF on cells already expressing GDNFR.
- certain conditions may benefit from an increase in GDNF and/or neurturin responsiveness. It may, therefore, be beneficial to increase the number or binding affinity of GDNFRs in patients suffering from conditions responsive to GDNF and/or neurturin therapy. This could be achieved through gene therapy, whereby selective expression of recombinant GDNFR in appropriate cells is achieved, for example, by using GDNFR genes controlled by tissue specific or inducible promoters or by producing localized infection with replication defective viruses carrying a recombinant GDNFR gene.
- conditions which will benefit from GDNFR or combined GDNF or neurturin/GDNFR delivery include, but are not limited to, motor neuron disorders including amyotrophic lateral sclerosis, neurological disorders associated with diabetes, Parkinson's disease, Alzheimer's disease, and Huntington's chorea.
- GDNFR or combined GDNF or neurturin/GDNFR delivery are described above and further include the treatment of: glaucoma or other diseases and conditions involving retinal ganglion cell degeneration; sensory neuropathy caused by injury to, insults to, or degeneration of, sensory neurons; pathological conditions, such as inherited ret'"" 1 1 age, disease or injury-related retinopathies, in which photore ⁇ occurs and is responsible for vision loss; and injury or degener. sensory cells, such as hair cells and auditory neurons for prever hearing loss due to variety of causes.
- a recombinant GDNFR gene may be used to inactivate or "knock out" the endogenous gene (e.g., by homologous recombination) and thereby create a GDNFR deficient cell, tissue, or animal.
- a recombinant GDNFR- ⁇ gene may be engineered to contain an insertional mutation which inactivates GDNFR- ⁇ .
- Such a construct under the control of a suitable promoter, may be introduced into a cell, such as an embryonic stem cell, by any conventional technique including transfection, transduction, injection, etc. Cells containing the construct may then be selected, for example by G418 resistance. Cells which lack an intact GDNFR- ⁇ gene are then identified (e.
- GDNFR- ⁇ g., by Southern blotting or Northern blotting or assay of expression.
- Cells lacking an intact GDNFR- ⁇ gene may then be fused to early embryo cells to generate transgenic animals deficient in GDNFR.
- a comparison of such an animal with an animal not expressing endogenous GDNF would reveal that either the two phenotypes match completely or that they do not, implying the presence of additional GDNF-like factors or receptors.
- Such an animal may be used to define specific neuronal populations, or other in vivo processes, normally dependent upon GDNF. Thus, these populations or processes may be expected to be effected if the animal did not express GDNFR- ⁇ , and therefore, could not respond to GDNF. Similar constructs may be made and procedures followed for GRR2 and GRR3.
- GDNFR probes may be used to identify cells and tissues which are responsive to GDNF or neurturin in normal or diseased states.
- the present invention provides for methods for identifying cells which are responsive to GDNF or neurturin by detecting GDNFR expression in such cells.
- GDNFR expression may be evidenced by transcription of GDNFR mRNA or production of GDNFR protein.
- GDNFR expression may be detected using probes which identify GDNFR nucleic acid or protein or by detecting "tag" sequences artificially added to the GDNFR protein.
- nucleic acid probe which may be used to detect GDNFR expression is a nucleic acid probe, which may be used to detect GDNFR-encoding RNA by any method known in the art, including, but not limited to, in situ hybridization, Northern blot analysis, or PCR related techniques.
- Nucleic acid products of the invention may be labeled with detectable markers (such as radiolabels and non- isotopic labels such as biotin) and employed in hybridization processes to locate the human GDNFR gene position and/or the position of any related gene family in a chromosomal map. They may also be used for identifying human GDNFR gene disorders at the DNA level and used as gene markers for identifying neighboring genes and their disorders. Contemplated herein are kits containing such labeled materials.
- Polypeptide products of the invention may be "labeled" by association with a detectable marker substance or label (e.g., a radioactive isotope, a fluorescent or chemiluminescent chemical, an enzyme or other label available to one skilled in the art) to provide reagents useful in detection and quantification of GDNF or neurturin in solid tissue and fluid samples such as blood or urine.
- a detectable marker substance or label e.g., a radioactive isotope, a fluorescent or chemiluminescent chemical, an enzyme or other label available to one skilled in the art
- Such products may also be used in detecting cells and tissues which are responsive to GDNF or neurturin in normal or diseased states.
- Another possible assay for detecting the presence of GDNF or neurturin in a test sample or screening for the presence of a GDNF-like molecule involves contacting the test sample with a GDNFR protein, suitable for binding GDNF or neurturin, immobilized on a solid phase, thereby producing GDNFR-bound GDNF or neurturin protein.
- the GDNFR-bound GDNF or neurturin may optionally be contacted with a detection reagent, such as a labeled antibody specific for GDNF or neurturin, thereby forming a detectable product.
- a detection reagent such as a labeled antibody specific for GDNF or neurturin
- such devices include a solid phase containing or coated with an appropriate GDNFR protein.
- a method for analyzing a test sample for the presence of GDNF-like protein may involve contacting the sample to an assay reagent comprising GDNFR protein, wherein said GDNFR protein reacts with the GDNF-like protein present in the test sample and produces a detectable reaction product indicative of the presence of GDNF.
- the assay reagents provided herein may also be embodied as part of a kit or article of manufacture.
- Contemplated is an article of manufacture comprising a packaging material and one or more preparations of the presently provided nucleic acid or amino acid sequences.
- packaging material will comprise a label indicating that the preparation is useful for detecting GDNF, neurturin, GDNFR or GDNFR defects in a biological sample.
- the kit may optionally include materials to carry out such testing, such as reagents useful for performing protein analysis, DNA or RNA hybridization analysis, or PCR analysis on blood, urine, or tissue samples.
- GDNFR protein may be used as an immunogen to generate anti-GDNFR antibodies.
- the amino acid sequence of GDNFR may be analyzed in order to identify portions of the molecule which may be associated with increased immunogenicity.
- the amino acid sequence may be subjected to computer analysis to identify surface epitopes which present computer-generated plots of hydrophilicity, surface probability, flexibility, antigenic index, amphiphilic helix, amphiphilic sheet, and secondary structure of GDNFR.
- the amino acid sequences of GDNFR from different species could be compared, and relatively non-homologous regions identified; these non-homologous regions would be more likely to be immunogenic across various species.
- polypeptide fragments duplicating only a part of the continuous amino acid sequence or secondary conformations within GDNFR which fragments may possess one activity of mammalian GDNFR (e.g., immunological activity) and not others (e.g., GDNF protein binding activity).
- the production of antibodies can include the production of anti-peptide antibodies.
- the following exemplary peptides were synthesized using GDNFR sequences:
- Peptides SJP-6, 7, and 8 are identical in rat and human GDNFR- ⁇ .
- Peptides SJP-9 and 10 are derived from the rat sequence and are each one amino acid different from human. Both polyclonal and monoclonal antibodies may be made by methods known in the art using these peptides or other portions of GDNFR.
- Monoclonal antibodies directed against GDNFR may be prepared by any known technique which provides for the production of antibody molecules by continuous cell lines in culture.
- the hybridoma technique originally developed by Kohler and Milstein to produce monoclonal antibodies (Nature,
- Human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies also may be prepared for therapeutic use and may be made by any of numerous techniques known in the art (e.g., Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80:7308-7312, 1983; Kozbor et al., Immunology Today, 4:72-79, 1983; Olsson et al, Meth. Enzymol., 92:3-16, 1982).
- Chimeric antibody molecules may be prepared containing a mouse antigen-binding domain with human constant regions (Morrison et al., Proc. Natl. Acad. Sci. U.S.A., 81:6851, 1984; Takeda et al., Nature, 314:452, 1985).
- polyclonal antibodies various procedures known in the art also may be used for the production of polyclonal antibodies.
- various host animals including, but not limited to, rabbits, mice, rats, etc., can be immunized by injection with GDNFR protein, or a fragment or derivative thereof.
- Various adjuvants may be used to increase the immunological response, depending on the host species selected.
- Useful adjuvants include, but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and human adjuvants such as BCG (Bacille Calmette- Guerin) and Corynebacterium parvum.
- BCG Bacille Calmette- Guerin
- Corynebacterium parvum include, but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and human adjuvants such as BCG (Bacille Calmette- Guerin) and Corynebacterium parvum.
- a molecular clone of an antibody to a GDNFR epitope also may be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NX., 1982) may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof.
- Antibody molecules may be purified by known techniques, e.g., immunoabsorption or immunoaffinity chromatography, chromatographic methods such as high performance liquid chromatography, or a combination thereof, etc.
- the present invention provides for antibody molecules as well as fragments of such antibody molecules.
- Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
- such fragments include but are not limited to: the F(ab')2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
- Such selective binding molecules may themselves be alternatives to GDNFR protein, and may be formulated as a pharmaceutical composition.
- the present invention provides various polynucleotides encoding GDNFR proteins.
- the expression product or a derivative thereof is characterized by the ability to bind to GDNF or neurturin so that further interactions with signaling molecules can occur, thereby providing or enhancing GDNF or neurturin activity such as increasing dopamine uptake by dopaminergic cells.
- the polynucleotides may also be used in cell therapy or gene therapy applications.
- novel GDNFR protein and DNA sequences coding for all or part of such receptors are provided.
- Novel nucleic acid sequences of the invention are useful in securing expression in procaryotic or eucaryotic host cells of polypeptide products having at least a part of the primary structural conformation and one or more of the biological properties of recombinant human GDNFR.
- the nucleic acids may be purified and isolated, so that the desired coding region is useful to produce the present polypeptides.
- the nucleic acid sequence may be used for diagnostic purposes, as described more fully below.
- Exemplary DNA sequences of the present invention comprise nucleic acid sequences encoding the GDNFR- ⁇ amino acid sequences depicted in Figures 2 and 4 and set forth in SEQ.
- DNA sequences disclosed by the present invention include: (a) the GDNFR DNA sequences depicted in the Figures (and complementary strands); (b) a DNA sequence which hybridizes (under hybridization conditions disclosed in the cDNA library screening section below, or equivalent conditions or more stringent conditions) to the DNA sequence in subpart (a) or to fragments thereof; and (c) a DNA sequence which, but for the degeneracy of the genetic code, would hybridize to the DNA sequence in subpart (a).
- genomic DNA sequences encoding allelic variant forms of human GDNFR and/or encoding GDNFR from other mammalian species, and manufactured DNA sequences encoding GDNFR, fragments of GDNFR, and analogs of GDNFR which DNA sequences may incorporate codons facilitating transcription and translation of messenger RNA in microbial hosts.
- manufactured sequences may readily be constructed according to the methods known in the art as well as the methods described herein.
- Recombinant expression techniques may be used to produce these polynucleotides and express the various GDNFR proteins.
- a nucleic acid sequence which encodes a GDNFR protein into an appropriate vector, one skilled in the art can readily produce large quantities of the desired nucleotide sequence. The sequences can then be used to generate detection probes or amplification primers.
- a polynucleotide encoding a GDNFR protein can be inserted into an expression vector. By introducing the expression vector into an appropriate host, the desired GDNFR protein may be produced in large amounts.
- host/vector systems available for the propagation of nucleic acid sequences and/or the production of GDNFR proteins. These include, but are not limited to, plasmid, viral and insertional vectors, and prokaryotic and eukaryotic hosts.
- plasmid plasmid
- viral and insertional vectors plasmid
- prokaryotic and eukaryotic hosts prokaryotic and eukaryotic hosts.
- One skilled in the art can adapt a host/vector system which is capable of propagating or expressing heterologous DNA to produce or express the sequences of the present invention.
- the GDNFR proteins of the present invention are readily produced in commercial quantities with greater purity.
- the novel nucleic acid sequences include degenerate nucleic acid sequences encoding the GDNFR proteins specifically set forth in the Figures, sequences encoding variants of GDNFR proteins, and those nucleic acid sequences which hybridize, preferably under stringent hybridization conditions, to complements of these nucleic acid sequences (see, Maniatis et.
- Exemplary stringent hybridization conditions are hybridization in 4 x SSC at 62-67°C, followed by washing in 0.1 x SSC at 62-67°C for approximately an hour.
- exemplary stringent hybridization conditions are hybridization in 45- 55%o formamide, 4 x SSC at 40-45°C.
- DNA sequences which hybridize to the complementary sequences for GDNFR protein under relaxed hybridization conditions and which encode a GDNFR protein of the present invention are also included herein. Examples of such relaxed stringency hybridization conditions are 4 x SSC at 45-55°C or hybridization with 30-40% formamide at 40-45°C.
- nucleic acid sequence encoding a full length GDNFR protein or a fragment thereof may readily be prepared or obtained by a variety of means, including, without limitation, chemical synthesis, cDNA or genomic library screening, expression library screening, and/or PCR amplification of cDNA. These methods and others useful for preparing nucleic acid sequences are known in the art and are set forth, for example, by Sambrook et al.
- nucleic acid sequences encoding GDNFR are mammalian sequences. Chemical synthesis of a nucleic acid sequence which encodes a GDNFR protein can also be accomplished using methods known in the art, such as those set forth by Engels et al. (Angew. Chem. Intl. Ed., 28:716-734, 1989). These methods include, inter alia, the phosphotriester, phosphoramidite and H-phosphonate methods of nucleic acid sequence synthesis. A preferred method for such chemical synthesis is polymer-supported synthesis using standard phosphoramidite chemistry.
- the DNA encoding the desired polypeptide will be several hundred base pairs (bp) or nucleotides in length. Nucleic acid sequences larger than about 100 nucleotides can be synthesized as several fragments using these methods. The fragments can then be ligated together to form a sequence for the expression of a full length GDNFR protein or a portion thereof.
- a suitable nucleic acid sequence may be obtained by screening an appropriate cDNA library (i.e., a library prepared from one or more tissue source(s) believed to express the protein) or a genomic library (a library prepared from total genomic DNA).
- the source of the cDNA library is typically a tissue that is believed to express GDNFR in reasonable quantities.
- the source of the genomic library is any tissue or tissues from a mammalian species believed to harbor a gene encoding GDNFR.
- the library can be screened for the presence of the GDNFR cDNA/gene using one or more nucleic acid probes (such as oligonucleotides, cDNA or genomic DNA fragments based upon the presently disclosed sequences) that will hybridize selectively with GDNFR cDNA(s) or gene(s) present in the library.
- the probes typically used for such library screening usually encode a small region of the GDNFR nucleic acid sequence from the same or a similar species as the species from which the library was prepared. Alternatively, the probes may be degenerate, as discussed herein.
- Library screening is typically accomplished by annealing the oligonucleotide probe or cDNA to the clones in the library under conditions of stringency that prevent non-specific binding but permit binding (hybridization) of those clones that have a significant level of homology with the probe or primer.
- Typical hybridization and washing stringency conditions depend in part on the size (i.e., number of nucleotides in length) of the cDNA or oligonucleotide probe, and whether the probe is degenerate.
- the probability of obtaining a clone(s) is also considered in designing the hybridization solution (e.g., whether a cDNA or genomic library is being screened; if it is a cDNA library, the probability that the cDNA of interest is present at a high level).
- DNA fragments such as cDNAs
- typical hybridization conditions include those as set forth in Ausubel et al., eds., supra.
- the blot containing the library is washed at a suitable stringency, depending on several factors such as probe size, expected homology of probe to clone, type of library being screened, number of clones being screened, and the like.
- stringent washing solutions which are usually low in ionic strength and are used at relatively high temperatures
- One such stringent wash is 0.015 M NaCl, 0.005 M NaCitrate and 0.1 % SDS at 55-65°C.
- Another such stringent buffer is 1 mM Na2EDTA, 40 mM NaHPO4, pH 7.2, and 1% SDS at about
- a first protocol uses 6 X SSC with 0.05 percent sodium pyrophosphate at a temperature of between about 35 and 62°C, depending on the length of the probe. For example, 14 base probes are washed at 35-40°C, 17 base probes at 45-50°C, 20 base probes at 52-57°C, and 23 base probes at 57-63°C. The temperature can be increased 2-3°C where the background non-specific binding appears high.
- a second protocol uses tetramethylammonium chloride (TMAC) for washing.
- TMAC tetramethylammonium chloride
- PCR polymerase chain reaction
- poly(A)+RNA or total RNA is extracted from a tissue that expresses GDNFR.
- a cDNA is then prepared from the RNA using the enzyme reverse transcriptase (i.e., RT-PCR).
- Two primers, typically complementary to two separate regions of the GDNFR cDNA (oligonucleotides) are then added to the cDNA along with a polymerase such as Taq polymerase, and the polymerase amplifies the cDNA region between the two primers.
- the method of choice for preparing the nucleic acid sequence encoding the desired GDNFR protein requires the use of oligonucleotide primers or probes (e.g., PCR, cDNA or genomic library screening)
- the oligonucleotide sequences selected as probes or primers should be of adequate length and sufficiently unambiguous so as to minimize the amount of non-specific binding that will occur during library screening or PCR amplification.
- the actual sequence of the probes or primers is usually based on conserved or highly homologous sequences or regions from the same or a similar gene from another organism, such as the rat nucleic acid sequence involved in the present invention.
- the probes or primers can be fully or partially degenerate, i.e., contain a mixture of probes/primers, all encoding the same amino acid sequence, but using different codons to do so.
- An alternative to preparing degenerate probes is to place an inosine in some or all of those codon positions that vary by species.
- the oligonucleotide probes or primers may be prepared by chemical synthesis methods for DNA as described above.
- GDNFR proteins based on these nucleic acid sequences encoding GDNFR, as well as mutant or variant sequences thereof, are also contemplated as within the scope of the present invention.
- Mutant or variant sequences include those sequences containing one or more nucleotide substitutions, deletions, and/or insertions as compared to the wild type sequence and that results in the expression of amino acid sequence variations as compared to the wild type amino acid sequence.
- naturally occurring GDNFR amino acid mutants or variants may exist, due to the existence of natural allelic variation.
- GDNFR proteins based on such naturally occurring mutants or variants are also within the scope of the present invention. Preparation of synthetic mutant sequences is also well known in the art, and is described for example in Wells et al. (Gene, 34:315, 1985) and in Sambrook et al., supra.
- nucleic acid and/or amino acid variants of naturally occurring GDNFR may be produced using site directed mutagenesis or PCR amplification where the primer(s) have the desired point mutations (see Sambrook et al., supra, and Ausubel et al., supra, for descriptions of mutagenesis techniques). Chemical synthesis using methods described by Engels et al., supra, may also be used to prepare such variants. Other methods known to the skilled artisan may be used as well.
- Preferred nucleic acid variants are those containing nucleotide substitutions accounting for codon preference in the host cell that is to be used to recombinantly produce GDNFR.
- Other preferred variants are those encoding conservative amino acid changes (e.g., wherein the charge or polarity of the naturally occurring amino acid side chain is not altered substantially by substitution with a different amino acid) as compared to wild type, and/or those designed to either generate a novel glycosylation and/or phosphorylation site(s) on GDNFR, or those designed to delete an existing glycosylation and/or phosphorylation site(s) on GDNFR.
- Yet other preferred variants are those encoding a GDNFR based upon a GDNFR consensus sequence as depicted in the Figures. Vectors
- the cDNA or genomic DNA encoding the desired GDNFR protein is inserted into a vector for further cloning (amplification of the DNA) or for expression.
- Suitable vectors are commercially available, or the vector may be specially constructed.
- Possible vectors include, but are not limited to, cosmids, plasmids or modified viruses, but the vector system must be compatible with the selected host cell.
- Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322, pUC, or Bluescript® plasmid derivatives (Stratagene, La Jolla CA).
- the recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, or other known techniques.
- the GDNFR-encoding nucleic acid sequence is inserted into a cloning vector which is used to transform, transfect, or infect appropriate host cells so that many copies of the nucleic acid sequence are generated.
- a cloning vector which has complementary cohesive termini. If the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. It also may prove advantageous to incorporate restriction endonuclease cleavage sites into the oligonucleotide primers used in polymerase chain reaction to facilitate insertion of the resulting nucleic acid sequence into vectors.
- any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.
- the cleaved vector and GDNFR-encoding nucleic acid sequence may be modified by homopolymeric tailing.
- transformation of host cells with recombinant DNA molecules that incorporate an isolated GDNFR gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene.
- the GDNFR-encoding nucleic acid sequence may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.
- the selection or construction of the appropriate vector will depend on 1) whether it is to be used for DNA amplification or for DNA expression, 2) the size of the DNA to be inserted into the vector, and 3) the host cell (e.g., mammalian, insect, yeast, fungal, plant or bacterial cells) to be transformed with the vector.
- Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and its compatibility with the intended host cell.
- the vector components may include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more selection or marker genes, enhancer elements, promoters, a transcription termination sequence, and the like. These components may be obtained from natural sources or synthesized by known procedures.
- the vectors of the present invention involve a nucleic acid sequence which encodes the GDNFR protein of interest operatively linked to one or more amplification, expression control, regulatory or similar operational elements capable of directing, controlling or otherwise effecting the amplification or expression of the GDNFR-encoding nucleic acid sequence in the selected host cell.
- Expression vectors containing GDNFR nucleic acid sequence inserts can be identified by three general approaches: (a) DNA-DNA hybridization; (b) the presence or absence of "marker" gene functions, and (c) the expression of inserted sequences.
- the presence of a foreign nucleic acid sequence inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences that are homologous to an inserted GDNFR-encoding nucleic acid sequence.
- the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a foreign nucleic acid sequence into the vector.
- certain "marker" gene functions e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
- recombinant expression vectors can be identified by detecting the foreign protein product expressed by the recombinant nucleic acid sequence.
- Such assays can be based on the physical or functional properties of the expressed GDNFR protein product, for example, by binding of the GDNFR- ⁇ protein to GDNF or to an antibody which directly recognizes GDNFR- ⁇ .
- the signal sequence may be a component of the vector, or it may be a part of GDNFR DNA that is inserted into the vector.
- the native GDNFR DNA encodes a signal sequence at the amino terminus of the protein that is cleaved during post- translational processing of the protein to form the mature GDNFR protein.
- GDNFR polynucleotides with the native signal sequence as well as GDNFR polynucleotides wherein the native signal sequence is deleted and replaced with a heterologous signal sequence.
- the heterologous signal sequence selected should be one that is recognized and processed, i.e., cleaved by a signal peptidase, by the host cell.
- the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, or heat-stable enterotoxin II leaders.
- a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, or heat-stable enterotoxin II leaders.
- yeast secretion the native GDNFR signal sequence may be substituted by the yeast invertase, alpha factor, or acid phosphatase leaders.
- the native signal sequence is satisfactory, although other mammalian signal sequences may be suitable.
- Expression and cloning vectors generally include a nucleic acid sequence that enables the vector to replicate in one or more selected host cells.
- this sequence is typically one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences.
- origins of replication or autonomously replicating sequences are well known for a variety of bacteria, yeasts, and viruses.
- the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria and various origins (e.g., SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.
- the origin of replication component is not needed for mammalian expression vectors (for example, the S V40 origin is often used only because it contains the early promoter).
- the expression and cloning vectors may contain a selection gene. This gene encodes a "marker" protein necessary for the survival or growth of the transformed host cells when grown in a selective culture medium. Host cells that were not transformed with the vector will not contain the selection gene, and therefore, they will not survive in the culture medium.
- Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from the culture medium. Other selection genes may be used to amplify the gene which will be expressed.
- Amplification is the process wherein genes which are in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells.
- suitable selectable markers for mammalian cells include dihydrofolate reductase (DHFR) and thymidine kinase.
- DHFR dihydrofolate reductase
- thymidine kinase thymidine kinase.
- the mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of the marker present in the vector. Selection pressure is imposed by culturing the transformed cells under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to amplification of both the selection gene and the DNA that encodes GDNFR.
- GDNFR GDNFR
- cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate, a competitive antagonist of DHFR.
- methotrexate a competitive antagonist of DHFR.
- An appropriate host cell when wild-type DHFR is used is the Chinese hamster ovary cell line deficient in DHFR activity (see, for example, Urlaub and Chasin, Proc. Natl. Acad. Sci., U.S.A., 77(7): 4216-4220, 1980).
- the transformed cells are then exposed to increased levels of methotrexate. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA present in the expression vector, such as the DNA encoding a GDNFR protein.
- the expression and cloning vectors of the present invention will typically contain a promoter that is recognized by the host organism and operably linked to the nucleic acid sequence encoding the GDNFR protein. Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of a particular nucleic acid sequence, such as that encoding GDNFR. Promoters are conventionally grouped into one of two classes, inducible promoters and constitutive promoters. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as the presence or absence of a nutrient or a change in temperature.
- promoters recognized by a variety of potential host cells, are well known. These promoters are operably linked to the DNA encoding GDNFR by removing the promoter from the source DNA by restriction enzyme digestion and inserting the desired promoter sequence into the vector.
- the native GDNFR promoter sequence may be used to direct amplification and/or expression of GDNFR DNA.
- a heterologous promoter is preferred, however, if it permits greater transcription and higher yields of the expressed protein as compared to the native promoter, and if it is compatible with the host cell system that has been selected for use.
- Promoters suitable for use with prokaryotic hosts include the beta-lactamase and lactose promoter systems; alkaline phosphatase, a tryptophan (trp) promoter system; and hybrid promoters such as the tac promoter. Other known bacterial promoters are also suitable. Their nucleotide sequences have been published, thereby enabling one skilled in the art to ligate them to the desired DNA sequence(s), using linkers or adaptors as needed to supply any required restriction sites.
- Suitable promoting sequences for use with yeast hosts are also well known in the art.
- Yeast enhancers are advantageously used with yeast promoters.
- Suitable promoters for use with mammalian host cells are well known and include those obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40).
- Other suitable mammalian promoters include heterologous mammalian promoters, e.g., heat-shock promoters and the actin promoter.
- a promoter for possible use in the production of GDNFR proteins in CHO cells is SRa (see Takebe et al, Mol. Cell. Biol., 8(1): 466-472, 1988).
- a suitable expression vector is pDSRa2.
- the pDSRa2 plasmid constructs containing the appropriate GDNFR cDNA may be prepared substantially in accordance with the process described in the co-owned and copending U. S. Patent Application Serial Number 501,904 filed March 29, 1990 (also see, European Patent Application No. 90305433, Publication No. EP 398 753, filed May 18, 1990 and WO 90/14363 (1990), the disclosures of which are hereby incorporated by reference.
- Additional promoters which may be of interest in controlling GDNFR expression include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, Nature, 290:304-310, 1981); the CMV promoter; the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., Cell, 22:787-797, 1980); the herpes thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. Sci.
- elastase I gene control region which is active in pancreatic acinar cells (Swift et al., Cell, 38:639-646, 1984; Ornitz et al., Cold Spring Harbor Symp. Quant. Biol.
- Enhancers are cis-acting elements of DNA, usually about 10-300 bp in length, that act on the promoter to increase its transcription. Enhancers are relatively orientation and position independent. They have been found 5' and 3' to the transcription unit.
- enhancer sequences available from mammalian genes are known (e.g., globin, elastase, albumin, alpha-feto-protein and insulin). Typically, however, an enhancer from a virus will be used.
- the SV40 enhancer, the cytomegalovirus early promoter enhancer, the polyoma enhancer, and adenovirus enhancers are exemplary enhancing elements for the activation of eukaryotic promoters. While an enhancer may be spliced into the vector at a position 5' or 3' to GDNFR DNA, it is typically located at a site 5' from the promoter.
- Transcription Termination Expression vectors used in eukaryotic host cells will also contain sequences necessary for terminating transcription and stabilizing the mRNA. Such sequences are commonly available from the 5' and occasionally 3' untranslated regions of eukaryotic DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding GDNFR.
- suitable vectors containing one or more of the above- listed components together with the desired GDNFR-encoding sequence is accomplished by standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the desired order to generate the plasmids required. To confirm that the correct sequences have been constructed, the ligation mixtures may be used to transform E. coli, and successful transformants may be selected by known techniques, such as ampicillin or tetracycline resistance as described above. Plasmids from the transformants may then be prepared, analyzed by restriction endonuclease digestion, and/or sequenced to confirm the presence of the desired construct.
- transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of the desired protein encoded by the expression vector.
- Transient expression systems comprising a suitable expression vector and a host cell, allow for the convenient positive identification of proteins encoded by cloned DNAs, as well as for the rapid screening of such proteins for desired biological or physiological properties. Thus, transient expression systems are particularly useful in identifying variants of the protein.
- Host cells e.g., bacterial, mammalian, insect, yeast, or plant cells transformed with nucleic acid sequences for use in expressing a recombinant GDNFR protein are also provided by the present invention.
- the transformed host cell is cultured under appropriate conditions permitting the expression of the nucleic acid sequence.
- suitable host cells and methods for transformation, culture, amplification, screening and product production and purification are well known in the art. See for example, Gething and Sambrook, Nature, 293: 620-625 (1981), or alternatively, Kaufman et al., Mol. Cell. Biol., 5 (7): 1750-1759 (1985) or Howley et al., U.S. Pat. No. 4,419,446.
- the transformed host cell is cultured in a suitable medium, and the expressed GDNFR protein is then optionally recovered, isolated and purified from the culture medium (or from the cell, if expressed intracellularly) by an appropriate means known to those skilled in the art.
- Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins.
- Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.
- expression in a bacterial system can be used to produce an unglycosylated core protein product.
- Expression in yeast may be used to produce a glycosylated product.
- Expression in mammalian cells can be used to ensure "native" glycosylation of the heterologous GDNFR protein.
- different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extents.
- Suitable host cells for cloning or expressing the vectors disclosed herein are prokaryote, yeast, or higher eukaryote cells.
- Eukaryotic microbes such as filamentous fungi or yeast may be suitable hosts for the expression of GDNFR proteins.
- Saccharomyces cerevisiae, or common baker's yeast is the most commonly used among lower eukaryotic host microorganisms, but a number of other genera, species, and strains are well known and commonly available.
- Host cells to be used for the expression of glycosylated GDNFR protein are also derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities.
- any higher eukaryotic cell culture might be used, whether such culture involves vertebrate or invertebrate cells, including plant and insect cells.
- the propagation of vertebrate cells in culture is a well known procedure.
- useful mammalian host cell lines include, but are not limited to, monkey kidney CV1 line transformed by SV40 (COS7), human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture), baby hamster kidney cells, and Chinese hamster ovary cells.
- Other suitable mammalian cell lines include but are not limited to, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines.
- Suitable host cells also include prokaryotic cells.
- Prokaryotic host cells include, but are not limited to, bacterial cells, such as Gram-negative or Gram- positive organisms, for example, E. coli, Bacilli such as B. subtilis, Pseudomonas species such as P. aeruginosa, Salmonella typhimurium, or Serratia marcescans.
- E. coli e.g., HB101, DH5a, DH10, and MC1061
- Various strains of Streptomyces spp. and the like may also be employed.
- Presently preferred host cells for producing GDNFR proteins are bacterial cells (e.g., Escherichia coli) and mammalian cells (such as Chinese hamster ovary cells, COS cells, etc.)
- the host cells are transfected and preferably transformed with the above- described expression or cloning vectors and cultured in a conventional nutrient medium.
- the medium may be modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
- Transfection and transformation are performed using standard techniques which are well known to those skilled in the art and which are selected as appropriate to the host cell involved. For example, for mammalian cells without cell walls, the calcium phosphate precipitation method may be used. Electroporation, micro injection and other known techniques may also be used.
- Culturing the Host Cells Transformed cells used to produce GDNFR proteins of the present invention are cultured in suitable media.
- the media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as gentamicin), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or other energy source.
- Other supplements may also be included, at appropriate concentrations, as will be appreciated by those skilled in the art.
- Suitable culture conditions such as temperature, pH, and the like, are also well known to those skilled in the art for use with the selected host cells.
- GDNFR protein may be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
- GDNFR- ⁇ protein may be isolated by binding to an affinity column comprising GDNF or anti-GDNFR- ⁇ antibody bound to a stationary support.
- GRR2 protein may be isolated by binding to an affinity column comprising neurturin or anti-GRR2 antibody bound to a stationary support.
- GDNFR proteins may be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding GDNFR.
- homologous recombination methods may be used to modify a cell that contains a normally transcriptionally silent GDNFR gene or under expressed gene and thereby produce a cell which expresses GDNFR.
- Homologous recombination is a technique originally developed for targeting genes to induce or correct mutations in transcriptionally active genes (Kucherlapati, Prog, in Nucl. Acid Res. and Mol. Biol., 36:301, 1989).
- the DNA sequence to be inserted into the genome can be directed to a specific region of the gene of interest by attaching it to targeting DNA.
- the targeting DNA is DNA that is complementary (homologous) to a region of the genomic DNA. Small pieces of targeting DNA that are complementary to a specific region of the genome are put in contact with the parental strand during the DNA replication process. It is a general property of DNA that has been inserted into a cell to hybridize, and therefore, recombine with other pieces of endogenous DNA through shared homologous regions.
- this complementary strand is attached to an oligonucleotide that contains a mutation or a different sequence of DNA, it too is incorporated into the newly synthesized strand as a result of the recombination. As a result of the proofreading function, it is possible for the new sequence of DNA to serve as the template. Thus, the transferred DNA is incorporated into the genome.
- sequence of a particular gene is known, such as the nucleic acid sequence, the pre-pro sequence or expression control sequence of GDNFR presented herein
- a piece of DNA that is complementary to a selected region of the gene can be synthesized or otherwise obtained, such as by appropriate restriction of the native DNA at specific recognition sites bounding the region of interest. This piece serves as a targeting sequence upon insertion into the cell and will hybridize to its homologous region within the genome. If this hybridization occurs during DNA replication, this piece of DNA, and any additional sequence attached thereto, will act as an Okazaki fragment and will be backstitched into the newly synthesized daughter strand of DNA.
- a promoter/enhancer element, a suppresser, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired GDNFR protein.
- the control element does not encode GDNFR, but instead controls a portion of the DNA present in the host cell genome.
- the expression of GDNFR proteins may be achieved not by transfection of DNA that encodes the GDNFR gene itself, but rather by the use of targeting DNA (containing regions of homology with the endogenous gene of interest) coupled with DNA regulatory segments that provide the endogenous gene sequence with recognizable signals for transcription of a GDNFR protein.
- GDNFR analogs include polypeptides in which amino acids have been deleted from (“deletion variants"), inserted into (“addition variants"), or substituted for (“substitution variants") residues within the amino acid sequence of naturally-occurring GDNFR polypeptides including those depicted in the Figures.
- Such variants are prepared by introducing appropriate nucleotide changes into the DNA encoding the polypeptide or by in vitro chemical synthesis of the desired polypeptide. It will be appreciated by those skilled in the art that many combinations of deletions, insertions, and substitutions can be made to an amino acid sequence such as mature human GDNFR provided that the final molecule possesses GDNFR activity.
- Mutagenesis techniques for the replacement, insertion or deletion of one or more selected amino acid residues encoded by the nucleic acid sequences depicted in Figures 2 and 4 are well known to one skilled in the art (e.g., U.S. Pat. No.
- substitution variants There are two principal variables in the construction of substitution variants: the location of the mutation site and the nature of the mutation.
- the sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid modifications and then with more radical selections depending upon the results achieved, (2) deleting the target amino acid residue, or (3) inserting amino acid residues adjacent to the located site. Conservative changes in from 1 to 30 contiguous amino acids are preferred.
- N-terminal and C-terminal deletion GDNFR protein variants may also be generated by proteolytic enzymes.
- deletions generally range from about 1 to 30 contiguous residues, more usually from about 1 to 10 contiguous residues, and typically from about 1 to 5 contiguous residues.
- N-terminal, C-terminal and internal intrasequence deletions are contemplated.
- Deletions may be introduced into regions of the molecule which have low homology with non-human GDNFR to modify the activity of GDNFR. Deletions in areas of substantial homology with non-human GDNFR sequences will be more likely to significantly modify GDNFR biological activity. The number of consecutive deletions typically will be selected so as to preserve the tertiary structure of the GDNFR protein product in the affected domain, e.g., cysteine crosslinking.
- Non-limiting examples of deletion variants include truncated GDNFR protein products lacking N-terminal or C-terminal amino acid residues.
- truncated GDNFR protein products lacking N-terminal or C-terminal amino acid residues.
- GPI glycosyl-phosphatidylinositol
- amino acid sequence additions typically include N-and/or C-terminal fusions or terminal additions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as internal or medial additions of single or multiple amino acid residues.
- Polypeptides of the invention may also include an initial methionine amino acid residue (at position -1 with respect to the first amino acid residue of the desired polypeptide).
- Internal additions may range generally from about 1 to 10 contiguous residues, more typically from about 1 to 5 residues, and usually from about 1 to 3 amino acid residues.
- N-terminal addition variants include GDNFR with the inclusion of a heterologous N-terminal signal sequence to the N-terminus of GDNFR to facilitate the secretion of mature GDNFR from recombinant host cells and thereby facilitate harvesting or bioavailability.
- signal sequences generally will be obtained from, and thus be homologous to, the intended host cell species.
- Additions may also include amino acid sequences derived from the sequence of other neurotrophic factors. For example, it is contemplated that a fusion protein of GDNF and GDNFR- ⁇ , or neurturin and GRR2, may be produced, with or without a linking sequence, thereby forming a single molecule therapeutic entity.
- GDNFR substitution variants have one or more amino acid residues of the GDNFR amino acid sequence removed and a different residue(s) inserted in its place.
- substitution variants include allelic variants, which are characterized by naturally-occurring nucleotide sequence changes in the species population that may or may not result in an amino acid change.
- substitution variants may involve the replacement of single or contiguous amino acid residues at one or more different locations.
- Specific mutations of the GDNFR amino acid sequence may involve modifications to a glycosylation site (e.g., serine, threonine, or asparagine).
- An asparagine-linked glycosylation recognition site comprises a tripeptide sequence which is specifically recognized by appropriate cellular glycosylation enzymes. These tripeptide sequences are either Asn-Xaa-Thr or Asn-Xaa-Ser, where Xaa can be any amino acid other than Pro.
- a variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) result in non-glycosylation at the modified tripeptide sequence.
- the expression of appropriate altered nucleotide sequences produces variants which are not glycosylated at that site.
- the GDNFR amino acid sequence may be modified to add glycosylation sites.
- One method for identifying GDNFR amino acid residues or regions for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (Science, 244: 1081-1085, 1989).
- an amino acid residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell.
- Those domains demonstrating functional sensitivity to the substitutions may then be refined by introducing additional or alternate residues at the sites of substitution.
- the target site for introducing an amino acid sequence variation is determined, alanine scanning or random mutagenesis is conducted on the corresponding target codon or region of the DNA sequence, and the expressed GDNFR variants are screened for the optimal combination of desired activity and degree of activity.
- the sites of greatest interest for substitutional mutagenesis include sites where the amino acids found in GDNFR proteins from various species are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity.
- Other sites of interest are those in which particular residues of GDNFR-like proteins, obtained from various species, are identical. Such positions are generally important for the biological activity of a protein.
- Trp Tyr Tyr Tyr
- Y Phe Trp; Phe; Thr; Ser
- Conservative modifications to the amino acid sequence are expected to produce GDNFR protein products having functional and chemical characteristics similar to those of naturally occurring GDNFR.
- substantial modifications in the functional and/or chemical characteristics of GDNFR protein products may be accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
- Naturally occurring residues may be divided into groups based on common side chain properties:
- Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class. Such substituted residues may be introduced into regions of the human GDNFR protein that are homologous with non-human GDNFR proteins, or into the non-homologous regions of the molecule.
- GDNFR proteins include those biologically active molecules containing all or part of the amino acid sequences as depicted in the Figures, as well as consensus and modified sequences in which biologically equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change.
- one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
- Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
- the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
- the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
- the positively charged (basic) amino acids include arginine, lysine and histidine.
- the negatively charged (acidic) amino acids include aspartic acid and glutamic acid. It is also contemplated that the GDNFR proteins, analogs, or fragments or derivatives thereof may be differentially modified during or after translation, e.g., by phosphorylation, glycosylation, crosslinking, acylation, proteolytic cleavage, linkage to an antibody molecule, membrane molecule or other ligand.
- Chemically modified derivatives of GDNFR or GDNFR analogs may be prepared by one of skill in the art based upon the present disclosure.
- the chemical moieties most suitable for derivatization include water soluble polymers.
- a water soluble polymer is desirable because the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment.
- the polymer will be pharmaceutically acceptable for the preparation of a therapeutic product or composition.
- One skilled in the art will be able to select the desired polymer based on such considerations as whether the polymer/protein conjugate will be used therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis, and other considerations.
- the effectiveness of the derivatization may be ascertained by administering the derivative, in the desired form (e.g., by osmotic pump, or, more preferably, by injection or infusion, or, further formulated for oral, pulmonary or other delivery routes), and determining its effectiveness.
- the desired form e.g., by osmotic pump, or, more preferably, by injection or infusion, or, further formulated for oral, pulmonary or other delivery routes
- Suitable water soluble polymers include, but are not limited to, polyethylene glycol, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly- 1 , 3-dioxolane, poly- 1 ,3,6- trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n- vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
- Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
- the polymer may be of any molecular weight, and may be branched or unbranched.
- the preferred molecular weight is between about 2 kDa and about 100 kDa for ease in handling and manufacturing (the term "about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight).
- Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired; the effects, if any, on biological activity; the ease in handling; the degree or lack of antigenicity and other known effects of polyethylene glycol on a therapeutic protein or variant).
- polymer molecules so attached may vary, and one skilled in the art will be able to ascertain the effect on function.
- One may mono-derivatize, or may provide for a di-, tri-, tetra- or some combination of derivatization, with the same or different chemical moieties (e.g., polymers, such as different weights of polyethylene glycols).
- the proportion of polymer molecules to protein (or peptide) molecules will vary, as will their concentrations in the reaction mixture.
- the optimum ratio in terms of efficiency of reaction in that there is no excess unreacted protein or polymer
- the desired degree of derivatization e.g., mono, di-, tri-, etc.
- the molecular weight of the polymer selected whether the polymer is branched or unbranched, and the reaction conditions.
- the polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art. See for example, EP 0401 384, the disclosure of which is hereby incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp.
- polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group.
- Reactive groups are those to which an activated polyethylene glycol molecule may be bound.
- the amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residue.
- Those having a free carboxyl group may include aspartic acid residues, glutamic acid residues, and the C-terminal amino acid residue.
- Sulfhydrl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s).
- attachment at an amino group such as attachment at the N-terminus or lysine group is preferred. Attachment at residues important for receptor binding should be avoided if receptor binding is desired.
- polyethylene glycol as an illustration of the present compositions, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (or peptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein.
- the method of obtaining the N-terminally pegylated preparation i.e., separating this moiety from other monopegylated moieties if necessary
- Selective N-terminal chemical modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein.
- substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.
- one may selectively N-terminally pegylate the protein by performing the reaction at a pH which allows one to take advantage of the pKa differences between the e-amino group of the lysine residues and that of the a- amino group of the N-terminal residue of the protein.
- the water soluble polymer may be of the type described above, and should have a single reactive aldehyde for coupling to the protein.
- Polyethylene glycol propionaldehyde, containing a single reactive aldehyde, may be used.
- the present invention contemplates use of derivatives which are prokaryote-expressed GDNFR proteins, or variants thereof, linked to at least one polyethylene glycol molecule, as well as use of GDNFR proteins, or variants thereof, attached to one or more polyethylene glycol molecules via an acyl or alkyl linkage.
- Pegylation may be carried out by any of the pegylation reactions known in the art. See, for example: Focus on Growth Factors, 3 (2): 4-10, 1992;
- Pegylation may be carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer).
- Pegylation by acylation generally involves reacting an active ester derivative of polyethylene glycol (PEG) with the GDNFR protein or variant. Any known or subsequently discovered reactive PEG molecule may be used to carry out the pegylation of GDNFR protein or variant.
- a preferred activated PEG ester is PEG esterified to N-hydroxysuccinimide (NHS).
- acylation is contemplated to include without limitation the following types of linkages between the therapeutic protein and a water soluble polymer such as PEG: amide, carbamate, urethane, and the like. See Bioconjugate Chem., 5: 133-140, 1994. Reaction conditions may be selected from any of those known in the pegylation art or those subsequently developed, but should avoid conditions such as temperature, solvent, and pH that would inactivate the GDNFR or variant to be modified.
- Pegylation by acylation will generally result in a poly-pegylated GDNFR protein or variant.
- the connecting linkage will be an amide.
- the resulting product will be substantially only (e.g., > 95%) mono, di- or tri-pegylated.
- some species with higher degrees of pegylation may be formed in amounts depending on the specific reaction conditions used.
- more purified pegylated species may be separated from the mixture, particularly unreacted species, by standard purification techniques, including, among others, dialysis, salting-out, ultrafiltration, ion-exchange chromatography, gel filtration chromatography and electrophoresis.
- Pegylation by alkylation generally involves reacting a terminal aldehyde derivative of PEG with the GDNFR protein or variant in the presence of a reducing agent. Pegylation by alkylation can also result in poly-pegylated GDNFR protein or variant. In addition, one can manipulate the reaction conditions to favor pegylation substantially only at the a-amino group of the N-terminus of the GDNFR protein or variant (i.e., a mono-pegylated protein). In either case of monopegylation or polypegylation, the PEG groups are preferably attached to the protein via a -CH--NH- group. With particular reference to the -CH 2 - group, this type of linkage is referred to herein as an "alkyl" linkage.
- Derivatization via reductive alkylation to produce a monopegylated product exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization.
- the reaction is performed at a pH which allows one to take advantage of the pKa differences between the e-amino groups of the lysine residues and that of the a-amino group of the N-terminal residue of the protein.
- the present invention contemplates use of a substantially homogeneous preparation of monopolymer/GDNFR protein (or variant) conjugate molecules (meaning GDNFR protein or variant to which a polymer molecule has been attached substantially only (i.e., > 95%>) in a single location). More specifically, if polyethylene glycol is used, the present invention also encompasses use of pegylated GDNFR protein or variant lacking possibly antigenic linking groups, and having the polyethylene glycol molecule directly coupled to the GDNFR protein or variant.
- GDNFR protein products include pegylated GDNFR protein or variants, wherein the PEG group(s) is (are) attached via acyl or alkyl groups.
- PEG group(s) may be mono-pegylated or poly-pegylated (e.g., containing 2-6, and preferably 2-5, PEG groups).
- the PEG groups are generally attached to the protein at the a- or e-amino groups of amino acids, but it is also contemplated that the PEG groups could be attached to any amino group attached to the protein, which is sufficiently reactive to become attached to a PEG group under suitable reaction conditions.
- the polymer molecules used in both the acylation and alkylation approaches may be selected from among water soluble polymers as described above.
- the polymer selected should be modified to have a single reactive group, such as an active ester for acylation or an aldehyde for alkylation, preferably, so that the degree of polymerization may be controlled as provided for in the present methods.
- An exemplary reactive PEG aldehyde is polyethylene glycol propionaldehyde, which is water stable, or mono C1-C10 alkoxy or aryloxy derivatives thereof (see, U.S. Patent 5,252,714).
- the polymer may be branched or unbranched.
- the polymer(s) selected should have a single reactive ester group.
- the polymer(s) selected should have a single reactive aldehyde group.
- the water soluble polymer will not be selected from naturally-occurring glycosyl residues since these are usually made more conveniently by mammalian recombinant expression systems.
- the polymer may be of any molecular weight, and may be branched or unbranched.
- polyethylene glycol is meant to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono-(Cl-ClO) alkoxy- or aryloxy-polyethylene glycol.
- Methods for preparing a pegylated GDNFR protein product will generally comprise the steps of (a) reacting a GDNFR protein product with polyethylene glycol (such as a reactive ester or aldehyde derivative of PEG) under conditions whereby the protein becomes attached to one or more PEG groups, and (b) obtaining the reaction product(s).
- polyethylene glycol such as a reactive ester or aldehyde derivative of PEG
- the optimal reaction conditions for the acylation reactions will be determined case-by-case based on known parameters and the desired result. For example, the larger the ratio of PEG:protein, the greater the percentage of poly-pegylated product.
- Reductive alkylation to produce a substantially homogeneous population of mono-polymer/GDNFR protein product will generally comprise the steps of:
- the reductive alkylation reaction conditions are those which permit the selective attachment of the water soluble polymer moiety to the N-terminus of GDNFR protein or variant.
- Such reaction conditions generally provide for pKa differences between the lysine amino groups and the a-amino group at the N- terminus (the pKa being the pH at which 50% of the amino groups are protonated and 50% are not).
- the pH also affects the ratio of polymer to protein to be used. In general, if the pH is lower, a larger excess of polymer to protein will be desired (i.e., the less reactive the N-terminal a-amino group, the more polymer needed to achieve optimal conditions).
- the pH will generally fall within the range of 3-9, preferably 3-6.
- Another important consideration is the molecular weight of the polymer. In general, the higher the molecular weight of the polymer, the fewer polymer molecules may be attached to the protein. Similarly, branching of the polymer should be taken into account when optimizing these parameters. Generally, the higher the molecular weight (or the more branches) the higher the polyme ⁇ protein ratio. In general, for the pegylation reactions contemplated herein, the preferred average molecular weight is about 2 kDa to about 100 kDa.
- the preferred average molecular weight is about 5 kDa to about 50 kDa, particularly preferably about 12 kDa to about 25 kDa.
- the ratio of water-soluble polymer to GDNF protein or variant will generally range from 1 :1 to 100:1, preferably (for polypegylation) 1 :1 to 20:1 and (for monopegylation) 1 : 1 to 5 : 1.
- reductive alkylation will provide for selective attachment of the polymer to any GDNFR protein or variant having an a-amino group at the amino terminus, and provide for a substantially homogenous preparation of monopolymer/GDNFR protein (or variant) conjugate.
- monopolymer/GDNFR protein (or variant) conjugate is used here to mean a composition comprised of a single polymer molecule attached to a molecule of GDNFR protein or GDNFR variant protein.
- the monopolymer/GDNFR protein (or variant) conjugate typically will have a polymer molecule located at the N-terminus, but not on lysine amino side groups.
- the preparation will generally be greater than 90% monopolymer/GDNFR protein (or variant) conjugate, and more usually greater than 95%o monopolymer/GDNFR protein (or variant) conjugate, with the remainder of observable molecules being unreacted (i.e., protein lacking the polymer moiety).
- the GDNFR protein product may involve the preparation of a pegylated molecule involving a fusion protein or linked GDNFR and neurotrophic factor, such as GDNFR- ⁇ and GDNF molecules or GRR2 and neurturin molecules.
- the reducing agent should be stable in aqueous solution and preferably be able to reduce only the Schiff base formed in the initial process of reductive alkylation.
- Suitable reducing agents may be selected from sodium borohydride, sodium cyanoborohydride, dimethylamine borane, trimethylamine borane and pyridine borane.
- a particularly suitable reducing agent is sodium cyanoborohydride.
- Other reaction parameters, such as solvent, reaction times, temperatures, etc., and means of purification of products, can be determined case-by-case based on the published information relating to derivatization of proteins with water soluble polymers (see the publications cited herein).
- GDNFR protein product pharmaceutical compositions typically include a therapeutically or prophylactically effective amount of GDNFR protein product in admixture with one or more pharmaceutically and physiologically acceptable formulation materials selected for suitability with the mode of administration.
- suitable formulation materials include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants.
- a suitable vehicle may be water for injection, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration.
- Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles.
- pharmaceutically acceptable carrier or “physiologically acceptable carrier” as used herein refers to a formulation material(s) suitable for accomplishing or enhancing the delivery of the GDNFR protein product as a pharmaceutical composition.
- the primary solvent in a vehicle may be either aqueous or non-aqueous in nature.
- the vehicle may contain other formulation materials for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation.
- the vehicle may contain additional formulation materials for modifying or maintaining the rate of release of GDNFR protein product, or for promoting the absorption or penetration of GDNFR protein product across the blood-brain barrier.
- the therapeutic pharmaceutical composition Once the therapeutic pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready to use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.
- the optimal pharmaceutical formulation will be determined by one skilled in the art depending upon the intended route of administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed.
- compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives.
- the GDNFR protein product pharmaceutical composition also may be formulated for parenteral administration.
- Such parenterally administered therapeutic compositions are typically in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the GDNFR protein product in a pharmaceutically acceptable vehicle.
- a pharmaceutically acceptable vehicle is physiological saline.
- the GDNFR protein product pharmaceutical compositions also may include particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation.
- a particularly suitable vehicle for parenteral injection is sterile distilled water in which the GDNFR protein product is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation may involve the formulation of the GDNFR protein product with an agent, such as injectable microspheres or liposomes, that provides for the slow or sustained release of the protein which may then be delivered as a depot injection.
- Other suitable means for the introduction of GDNFR protein product include implantable drug delivery devices which contain the GDNFR protein product.
- the preparations of the present invention may include other components, for example parenterally acceptable preservatives, tonicity agents, cosolvents, wetting agents, complexing agents, buffering agents, antimicrobials, antioxidants and surfactants, as are well known in the art.
- suitable tonicity enhancing agents include alkali metal halides (preferably sodium or potassium chloride), mannitol, sorbitol and the like.
- suitable preservatives include, but are not limited to, benzalkonium chloride, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid and the like. Hydrogen peroxide may also be used as preservative.
- Suitable cosolvents are for example glycerin, propylene glycol and polyethylene glycol.
- Suitable complexing agents are for example caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta- cyclodextrin.
- Suitable surfactants or wetting agents include sorbitan esters, polysorbates such as polysorbate 80, tromethamine, lecithin, cholesterol, tyloxapal and the like.
- the buffers can be conventional buffers such as borate, citrate, phosphate, bicarbonate, or Tris-HCl.
- the formulation components are present in concentration that are acceptable to the site of administration.
- buffers are used to maintain the composition at physiological pH or at slightly lower pH, typically within a pH range of from about 5 to about 8.
- a pharmaceutical composition may be formulated for inhalation.
- the GDNFR protein product may be formulated as a dry powder for inhalation.
- GDNFR protein product inhalation solutions may also be formulated in a liquefied propellant for aerosol delivery.
- solutions may be nebulized.
- GDNFR protein product which is administered in this fashion may be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules.
- a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional formulation materials may be included to facilitate absorption of GDNFR protein product.
- Diluents flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.
- Another preparation may involve an effective quantity of GDNFR protein product in a mixture with non-toxic excipients which are suitable for the manufacture of tablets.
- excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.
- GDNFR protein product formulations will be evident to those skilled in the art, including formulations involving GDNFR protein product in combination with GDNF protein product.
- Techniques for formulating a variety of other sustained- or controlled-delivery means such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See, for example, Supersaxo et al. description of controlled release porous polymeric microparticles for the delivery of pharmaceutical compositions (International Publication No. WO 93/15722; International Application No. PCT/US93/00829) the disclosure of which is hereby incorporated by reference.
- GDNFR protein product may be administered parenterally via a variety of routes, including subcutaneous, intramuscular, intravenous, transpulmonary, transdermal, intrathecal and intracerebral delivery.
- protein factors that do not readily cross the blood-brain barrier may be given directly intracerebrally or otherwise in association with other elements that will transport them across the barrier.
- the GDNFR protein product may be administered intracerebroventricularly or into the brain or spinal cord subarachnoid space.
- GDNFR protein product may also be administered intracerebrally directly into the brain parenchyma.
- GDNFR protein product may be administered extracerebrally in a form that has been modified chemically or packaged so that it passes the blood- brain barrier, or with one or more agents capable of promoting penetration of
- GDNFR protein product across the barrier For example, a conjugate of NGF and monoclonal anti-transferrin receptor antibodies has been shown to be transported to the brain via binding to transferrin receptors.
- GDNFR protein product may be administered continuously or periodically from a constant- or programmable- flow implanted pump.
- Slow-releasing implants containing the neurotrophic factor embedded in a biodegradable polymer matrix can also deliver GDNFR protein product.
- the frequency of dosing will depend on the pharmacokinetic parameters of the GDNFR protein product as formulated, and the route and site of administration. Regardless of the manner of administration, the specific dose may be calculated according to body weight, body surface area or organ size. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose- response data.
- the final dosage regimen involved in a method for treating a specific injury or condition will be determined by the attending physician.
- an effective amount of the GDNFR protein product will be determined by considering various factors which modify the action of drugs, e.g., the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. See, Remington's Pharmaceutical Sciences, supra, at pages 697-773, herein incorporated by reference.
- GDNFR- ⁇ is used to enhance GDNF action
- the GDNFR- ⁇ dose is selected to be similar to that required for GDNF therapy
- the GDNFR- ⁇ dose would be several times the GDNF dose. Dosing may be one or more times daily, or less frequently, and may be in conjunction with other compositions as described herein. It should be noted that the present invention is not limited to the dosages recited herein.
- GDNFR protein products may be advantageous for a given treatment. While continuous administration may be accomplished via a mechanical means, such as with an infusion pump, it is contemplated that other modes of continuous or near continuous administration may be practiced. For example, chemical derivatization or encapsulation may result in sustained release forms of the protein which have the effect of continuous presence in the bloodstream, in predictable amounts, based on a determined dosage regimen.
- GDNFR protein products include proteins derivatized or otherwise formulated to effectuate such continuous administration. Sustained release forms of the GDNFR protein products will be formulated to provide the desired daily or weekly effective dosage. It is further contemplated that the GDNFR protein product may be administered in a combined form with GDNF and/or neurturin. Alternatively, the GDNFR protein product may be administered separately form a neurotrophic factor, either sequentially or simultaneously.
- GDNFR protein product of the present invention may also be employed, alone or in combination with other growth factors in the treatment of nerve disease.
- other factors or other molecules including chemical compositions, may be employed together with a GDNFR protein product.
- GDNFR protein product in the treatment of Parkinson's Disease, it is contemplated that GDNFR protein product be used by itself or in conjunction with the administration of Levodopa, wherein the GDNFR would enhance the activity of endogenous GDNF and thereby enhance the neuronal uptake of the increased concentration of dopamine.
- additional neurotrophic or neuron nurturing factors will be useful or necessary to treat some neuronal cell populations or some types of injury or disease.
- GDNFR or a combination of GDNFR and a neurotrophic factor such as GDNF or neurturin include, but are not limited to: mitogens such as insulin, insulin-like growth factors, epidermal growth factor, vasoactive growth factor, pituitary adenylate cyclase activating polypeptide, interferon and somatostatin; neurotrophic factors such as nerve growth factor, brain derived neurotrophic factor, neurotrophin-3, neurotrophin-4/5, neurotrophin-6, insulin-like growth factor, ciliary neurotrophic factor, acidic and basic fibroblast growth factors, fibroblast growth factor-5, transforming growth factor- ⁇ , cocaine-amphetamine regulated transcript (CART); and other growth factors such as epidermal growth factor, leukemia inhibitory factor, interleukins, interferons, and colony stimulating factors; as well as molecules and materials which are the functional equivalents to these factors.
- mitogens such as insulin, insulin-like growth factors, epidermal growth factor, vasoactive
- GDNFR protein product cell therapy e.g., intracerebral implantation of cells producing GDNFR protein product
- This embodiment would involve implanting into patients cells capable of synthesizing and secreting a biologically active form of GDNFR protein product.
- GDNFR protein product-producing cells may be cells that are natural producers of GDNFR protein product or may be recombinant cells whose ability to produce GDNFR protein product has been augmented by transformation with a gene encoding the desired GDNFR protein product.
- Such a modification may be accomplished by means of a vector suitable for delivering the gene as well as promoting its expression and secretion.
- the natural cells producing GDNFR protein product be of human origin and produce human GDNFR protein product.
- the recombinant cells producing GDNFR protein product be transformed with an expression vector containing a gene encoding a human GDNFR protein product.
- Implanted cells may be encapsulated to avoid infiltration of surrounding tissue.
- Human or non-human animal cells may be implanted in patients in biocompatible, semipermeable polymeric enclosures or membranes that allow release of GDNFR protein product, but that prevent destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissue.
- the patient's own cells, transformed to produce GDNFR protein product ex vivo could be implanted directly into the patient without such encapsulation.
- In vivo and in vitro gene therapy delivery of GDNFR protein product is also envisioned.
- In vitro gene therapy may be accomplished by introducing the gene coding for GDNFR protein product into targeted cells via local injection of a nucleic acid construct or other appropriate delivery vectors.
- a nucleic acid sequence encoding a GDNFR protein product may be contained in an adeno-associated virus vector for delivery into the targeted cells (e.g., Johnson, International Publication No. WO 95/34670; International Application No. PCT/US95/07178 the disclosure of which is hereby incorporated by reference).
- Alternative viral vectors include, but are not limited to, retrovirus, adenovirus, herpes simplex virus and papilloma virus vectors.
- Physical transfer either in vivo or ex vivo as appropriate, may also be achieved by liposome- mediated transfer, direct injection (naked DNA), receptor-mediated transfer (ligand- DNA complex), electroporation, calcium phosphate precipitation or microparticle bombardment (gene gun).
- GDNFR protein product gene therapy or cell therapy can further include the delivery of GDNF protein product.
- the host cell may be modified to express and release both GDNFR- ⁇ protein product and GDNF, or GRR2 and neurturin.
- the GDNFR- ⁇ and GDNF protein products may be expressed in and released from separate cells.
- Such cells may be separately introduced into the patient or the cells may be contained in a single implantable device, such as the encapsulating membrane described above.
- GDNFR protein product formulations described herein may be used for veterinary as well as human applications and that the term "patient” should not be construed in a limiting manner. In the case of veterinary applications, the dosage ranges may be determined as described above.
- Expression cloning involved the selection of a source of mRNA which is likely to contain significant levels of the target transcript. Retina photoreceptor cells were identified as responsive to GDNF at very low concentrations, suggesting the existence of a functional, high affinity receptor. To confirm that rat photoreceptor cells did express a high affinity receptor for GDNF, [ 12 5l]GDNF binding and photographic emulsion analysis were carried out.
- the neural retinas of 5-day-old C57B1/6 mouse pups or 3-day-old Sprague- Dawley rat pups were carefully removed and dissected free of the pigment epithelium, cut into 1 mm 2 fragments and placed into ice-cold phosphate-buffered saline (PBS).
- PBS ice-cold phosphate-buffered saline
- the retinas were then transferred into 10 mL of Hank's balanced salt solution (HBSS) containing 120 units papain and 2000 units DNAase and incubated for 20 minutes at 37°C on a rotary platform shaker at about 200 rpm.
- HBSS Hank's balanced salt solution
- the cells were then dispersed by trituration through fire- polished Pasteur pipettes, sieved through a 20 ⁇ m Nitex nylon mesh and centrifuged for five minutes at 200 x g .
- the resulting cell pellet was resuspended into HBSS containing 1% ovalbumin and 500 units DNAase, layered on top of a 4 % ovalbumin solution (in HBSS) and centrifuged for 10 minutes at 500 x g.
- the final pellet was resuspended in complete culture medium (see below), adjusted to about 15,000 cells/mL, and seeded in 90 ⁇ l aliquots into tissue culture plates coated with polyornithine and laminin as previously described (Louis et al., Journal Of Pharmacology And Experimental Therapeutics, 262, 1274-1283, 1992).
- the culture medium consisted of a 1 :1 mixture of Dulbecco's Modified Eagle's Medium (DMEM) and F12 medium, and was supplemented with 2.5% heat- inactivated horse serum (Hyclone, Logan, UT), B27 medium supplement (GIBCO, Grand Island, NY), D-glucose (final concentration: 5mg/mL), L-glutamine (final concentration: 2mM), 20 mM HEPES, bovine insulin and human transferrin (final concentrations: 2.5 and 0.1 mg/mL, respectively).
- DMEM Dulbecco's Modified Eagle's Medium
- F12 F12 medium
- Photoreceptors were identified by immunostaining for arrestin, a rod-specific antigen. Cultures of photoreceptors were fixed for 30 minutes at room temperature with 4% paraformaldehyde in PBS, pH 7.4, followed by three washes in PBS. The fixed cultures were then incubated in Superblock blocking buffer (Pierce, Rockford, IL) , containing 1% Nonidet P-40 to increase the penetration of the antibodies.
- Superblock blocking buffer Pierce, Rockford, IL
- the anti-arrestin antibodies (polyclonal rabbit antibody against the synthetic peptide sequence of arrestin: Val-Phe-Glu-Glu-Phe-Ala-Arg-Gln-Asn-Leu-Lys-Cys) were then applied at a dilution of between 1 :2000 in the same buffer, and the cultures were incubated for one hour at 37°C on a rotary shaker. After three washes with PBS, the cultures were incubated for one hour at 37°C with goat-anti-rabbit IgG (Vectastain kit from Vector Laboratories, Burlingame, CA) at a 1 :500 dilution.
- goat-anti-rabbit IgG Vectastain kit from Vector Laboratories, Burlingame, CA
- the secondary antibodies were then labeled with an avidin-biotin- peroxidase complex diluted at 1 :500 (45 minutes at 37°C).
- the labeled cell cultures were reacted for 5-20 minutes in a solution of 0.1 M Tris-HCl, pH 7.4, containing 0.04% 3',3'-diaminobenzidine-(HCl)4, 0.06 percent NiCl2 and 0.02 percent hydrogen peroxide. Based on arrestin-immunoreactivity, about 90% of the cells in the cultures were rod photoreceptors.
- the survival of photoreceptors was determined by examination of arrestin- stained cultures with bright-light optics at 200X magnification. The number of arrestin-positive photoreceptors was counted in one diametrical 1 X 6 mm strip, representing about 20 percent of the total surface area of a 6 mm- well. Viable photoreceptors were characterized as having a regularly-shaped cell body, with a usually short axon-like process. Photoreceptors showing signs of degeneration, such as having irregular, vacuolated perikarya or fragmented neurites, were excluded from the counts (most of the degenerating photoreceptors, however, detached from the culture substratum). Cell numbers were expressed either as cells/6-mm well.
- Cultured rat retinal cells enriched for photoreceptors were treated with human recombinant GDNF (ten-fold serial dilutions ranging from 10 ng/mL to 1 pg/mL). The cultures were fixed after six days and immunostained for arrestin, a rod photoreceptor-specific antigen. In cultures that were not treated with GDNF, the number of photoreceptors declined steadily over time to reach about 25 percent of the initial number after six days in culture. Treatment of the cultures with GDNF resulted in an about two-fold higher number of viable arrestin-positive photoreceptors after six days in culture.
- GDNF neurotrophic factor
- GDNF binding and photographic emulsion analysis were carried out.
- Postnatal rat photoreceptor cells were seeded on plastic slide flaskettes (Nunc) at a density of 2800 cells/mm2, three to four days before the experiments. The cells were washed once with ice-cold washing buffer (Dulbecco's Modified Eagle's Medium (DMEM) containing 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), pH 7.5).
- DMEM Dulbecco's Modified Eagle's Medium
- HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
- the cells were incubated with various concentrations of [ 12 ⁇ I]GDNF in binding buffer (DMEM containing 25 mM HEPES, pH 7.5, and 2 mg/mL of bovine serum albumin (BSA)) in the presence or absence of 500 nM unlabeled GDNF at 4°C for four hours.
- binding buffer DMEM containing 25 mM HEPES, pH 7.5, and 2 mg/mL of bovine serum albumin (BSA)
- BSA bovine serum albumin
- Rat photoreceptor cells were selected as a possible source of a high affinity receptor for GDNF based upon their cell surface binding of radiolabeled GDNF and their ability to respond to very low concentrations of the ligand, as described in Example 1.
- a size-selected cDNA library of approximately 50,000 independent clones was constructed using a mammalian expression vector (a derivative of pSR, Takebe et al, 1988 supra) and mRNA isolated from cultured post-natal rat photoreceptor cells, by the methods described below.
- the library was divided into pools of approximately 1,500 to 2,000 independent clones and screened using an established expression cloning approach (Gearing et al., EMBO Journal, 8, 3667-3676, 1989).
- Plasmid DNA representing each pool of the library was prepared and transfected into COS7 cells grown on plastic microscope slide flaskettes (Nunc, Naperville, IL).
- the transfected cells were treated with [ 12 5l]GDNF, fixed with glutaraldehyde, dehydrated, and dipped in photographic emulsion for autoradiography. Following exposure for five days, the slides were developed and examined for the presence of cells covered by silver grains which indicated the binding of [ 2 ⁇ I]GDNF to the cell surface as a result of the cell's expression of a receptor for GDNF.
- EGF receptor transfected cells treated with [ 12 ⁇ I]EGF were used as a positive control.
- Rat retinal cells were harvested from postnatal day 3-7 rats and seeded into culture dishes coated with laminin and polyornithine at a density of approximately 5700 cells/mm 2 . After 3-4 days in culture, the population was estimated to contain approximately 80% photoreceptor cells. Total RNA was prepared from this culture by standard methods, and Poly A+ RNA was purified using a polyA-tract kit (Promega, Madison, WI). A cDNA library was constructed from the rat photoreceptor poly A+ RNA using the Gibco Superscript Choice System (Gibco/BRL, Gaithersburg, MD).
- Two micrograms of poly A+ RNA were mixed with 50 ng of random hexamers, heated to 70°C for 10 minutes and then quick- chilled on ice.
- First strand synthesis was carried out with 400U Superscript II RT at 37°C for one hour.
- Second strand synthesis was performed in the same tube after the addition of dNTPs, 10U of E. coli DNA ligase, 40U of E. coli DNA polymerase I, and 2U of E. coli RNase H. After two hours at 16°C, the cDNA ends were blunted by treatment with 10U of T4 polymerase for an additional five minutes at 16°C. Following isopropanol precipitation, EcoRI cloning sites were added to the cDNA by ligation overnight with 10 ⁇ g of unphosphorylated EcoRI adapter oligonucleotides.
- the EcoRI adapted cDNA was then phosphorylated and applied to a Sephacryl S-500 HR size fractionation column. Following loading, the column was washed with 100 ⁇ l aliquots of TEN buffer (10 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 25 mM NaCl), and 30 ⁇ l fractions were collected. Fractions 6 through 8, which contained approximately 34 ng of high molecular weight cDNA, were pooled and precipitated. The recovered EcoRI-adapted cDNA was ligated overnight with 50 ng of EcoRI cut vector pBJ5. Aliquots of the ligation mix containing about 15 ng cDNA each were transformed into competent cells (E.
- coli strain DH10B GDBCO/BRL, Gaithersburg, MD
- the transformation mixture was titered and then plated on 27 Amp/LB plates at a density of 1500 colonies/plate. Colonies were scraped from each plate and collected into 10 mL of Luria broth (LB) to make 27 pools of 1500 independent clones each. A portion of the cells from each pool was frozen in glycerol and the remainder was used to isolate plasmid DNA using a Qiagen tip-500 kit (Qiagen Inc., Chatsworth, CA).
- COS7 cells were seeded (220,000 cells/slide) on plastic slide flaskettes (Nunc) coated with ProNectin (10 ⁇ g/mL in phosphate buffered saline (PBS)) one day before transfection.
- PBS phosphate buffered saline
- 700 ⁇ l of Opti MEMI (GIBCO/BRL, Gaithersburg, MD) containing 2 ⁇ g cDNA was mixed gently with 35 ⁇ l of DEAE Dextran solution (10 mg/mL, Sigma, St. Louis, MO) in an Eppendorf tube. Cells were washed twice with PBS and incubated with the transfection mix for 30 minutes at 37°C in a 5% CO2 atmosphere.
- DMEM media containing 10% fetal calf serum (FCS) and 80 nM Chloroquine (Sigma, St. Louis, MO) were added to each flaskette.
- FCS fetal calf serum
- Chloroquine 80 nM Chloroquine
- the transfected COS7 cells were washed once with ice-cold washing buffer (DMEM containing 25 mM HEPES, pH 7.5) and incubated in ice- cold binding buffer (DMEM containing 25 mM HEPES, pH 7.5 and 2 mg/mL BSA) supplemented with 50 pM [ 1 5l]GDNF at 4°C for four hours.
- Cells were washed six times in ice-cold washing buffer, fixed with 2.5% glutaraldehyde at room temperature for five minutes, dehydrated sequentially with 50% and 70% ethanol, and then dipped in NTB-2 photographic emulsion (Eastman Kodak). After 4-5 day exposure at 4°C in dark, the slides were developed and screened by bright-field and dark-field microscopy.
- a single pool was identified which contained a putative GDNF receptor clone. Clones from this pool were plated on 60 plates at a density of 100 colonies/plate. Cells were scraped from each plate, collected in LB, and allowed to grow for 4-5 hours at 37°C. Frozen stocks and DNA preparations were made from each pool, as before, to generate 60 subpools containing 100 independent clones each. Two of these 60 subpools were identified as positive by the method described above, and clones from those pools were plated at low density to allow isolation of single colonies. Single colonies (384) were picked from each of the two subpools and grown for six hours in 200 ⁇ l LB in 96-well plates.
- DNA from positive, single clones was prepared and sequenced using an automated ABI373A DNA sequencer (Perkin/Elmer Applied Biosystems, Santa Clara, CA ) and dideoxy-dye-terminators, according to manufacturer's instructions. Comparison of GDNFR- ⁇ sequence with all available public databases was performed using the FASTA (Pearson and Lipman, Proceedings Of The National Academy Of Sciences U.S.A., 85, 2444-2448, 1988) program algorithm as described in the University of Wisconsin Genetics Computer Group package (Program Manual for the Wisconsin Package, Version 8, September 1994, Genetics Computer Group, Madison, WI).
- the coding sequence is flanked by a 5 '-untranslated region of 301 bp and a 3 '-untranslated region of 430 bp that does not contain a potential polyadenylation site.
- the presence of an in-frame stop codon upstream of the first ATG at base pair 302 and its surrounding nucleotide context indicate that this methionine codon is the most likely translation initiator site (Kozak, Nucleic Acids Research. 15, 8125-8148, 1987).
- the GDNFR- ⁇ polypeptide sequence has an N-terminal hydrophobic region of approximately 19 residues (methionine- 1 to alanine- 19, Figure 3) with the characteristics of a secretory signal peptide (von Heijne, Protein Sequences And Data Analysis. 1, 41-42, 1987; von Heijne, Nucleic Acids Research. 14, 4683-4690, 1986). No internal hydrophobic domain that could serve as a transmembrane domain was found.
- a carboxy-terminal hydrophobic region of 21 residues (leucine-448 to serine-468 in Figure 3) is present and may be involved in a glycosyl- phosphatidylinositol (GPI) anchorage of the receptor to the cytoplasmic membrane. Except for the presence of three potential N-linked glycosylation sites, no conserved sequence or structural motifs were found.
- the protein is extremely rich in cysteine (31 of the 468 amino acid residues) but their spacing is not shared with that of cysteine-rich domains found in the extracellular portions of known receptors.
- the GDNFR- ⁇ sequence was compared to sequences in available public databases using FASTA. The search did not reveal significant homology to other published sequences.
- a binding assay was performed in accordance with an assay method previously described by Jing et al.. (Journal Of Cell Biology, 110, 283-294, 1990).
- the assay involved the binding of [ 12 ⁇ I]GDNF to rat photoreceptor cells, COS7 cells or 293T cells which had been transfected to express GDNFR- ⁇ .
- Recombinant GDNFR- ⁇ expressed on the surface of 293T cells was able to bind GDNF specifically and with an affinity comparable to that observed for GDNF binding sites on rat retinal cells.
- Rat photoreceptor cells were prepared as described in Example 1 , above, and seeded at a density of 5.7 x 10 ⁇ cells/cm 2 two to three days before the assay in 24- well Costar tissue culture plates pre-coated with polyornithine and laminin.
- COS7 cells were seeded at a density of 2.5 x 10 4 cells/cm 2 one day before the assay and transfected with 10-20 ⁇ g of plasmid DNA using the DEAE-dextran-chloroquine method (Aruffo and Seed, Proceedings Of The National Academy Of Sciences U.S.A., 84, 8573-8577, 1987).
- Cells from each dish were removed and reseeded into 30 wells of 24- well Costar tissue culture plates 24 hours following the transfection, and allowed to grow for an additional 48 hours. Cells were then left on ice for 5 to 10 minutes, washed once with ice-cold washing buffer and incubated with 0.2 mL of binding buffer containing various concentrations of [ 12 ⁇ I]GDNF with or without unlabeled GDNF at 4°C for four hours. Cells were washed four times with 0.5 mL ice-cold washing buffer and lysed with 0.5 mL of 1 M NaOH. The lysates were counted in a 1470 Wizard Automatic Gamma Counter.
- transiently transfected 293T cells were used (see below for 293T cell transfection). Two days following transfection, cells were removed from dishes by 2x versine. Cells were pelleted, washed once with ice-cold binding buffer and resuspended in ice-cold binding buffer at a density of 3 x 10 ⁇ cells/mL. The cell suspension was divided into aliquots containing 1.5 x 10 ⁇ cell/sample. Cells were then pelleted and incubated with various concentrations of [ 125 I]GDNF in the presence or absence of 500 nM of unlabeled GDNF at 4°C for four hours with gentle agitation.
- GDNFR- ⁇ mRNA The pattern of expression of GDNFR- ⁇ mRNA in embryonic mouse, adult mouse, rat, and human tissues was examined by Northern blot analysis.
- the cloned rat GDNFR- ⁇ cDNA was labeled using the Random Primed DNA Labeling Kit (Boehringer Mannheim, Indianapolis, IN) according to the manufacturer's procedures.
- Rat, mouse, and human tissue RNA blots purchased from Clontech, Palo Alto, CA were hybridized with the probe and washed using the reagents of the ExpressHyb Kit (Clontech) according to the manufacturer's instructions.
- GDNFR- ⁇ mRNA Tissue Northern blots prepared from adult rat, mouse, and human tissues indicated that GDNFR- ⁇ mRNA is most highly expressed in liver, brain, and kidney. High mRNA expression was also detected in lung, with lower or non-detectable amounts in spleen, intestine, testis, and skeletal muscle. In blots made from mRNA isolated from mouse embryo, expression was undetectable at embryonic day 7, became apparent at day El l, and was very high by day E 17. GDNFR- ⁇ mRNA was expressed in tissue isolated from several subregions of adult human brain at relatively equal levels. Expression of GDNFR- ⁇ mRNA in human adult brain showed little specificity for any particular region.
- transcripts of two distinct sizes were present. In mouse and human tissues, transcripts of 8.5 and 4.4 kb were found, while in rat the transcripts were 8.5 and 3.6 kb. The relative amounts of the larger and smaller transcripts varied with tissue type, the smaller transcript being predominant in liver and kidney and the larger being more abundant in brain.
- the binding of GDNF to 293T cells transfected with a GDNFR- ⁇ cDNA clone in the pBKRSV vector was examined by Scatchard analysis. Two classes of binding sites were detected, one with a binding affinity in the low picomolar range and another with an affinity of about 500 pM.
- the filters were then screened by hybridization with the radiolabeled probe.
- the filters were prehybridized in 200 mL of 6 x SSC, 1 x Denhardts, 0.5% SDS, 50 ⁇ g/mL salmon sperm DNA at 55°C for 3.5 hours. Following the addition of 2 x 10 8 cpm of the radiolabeled probe, hybridization was continued for 18 hours. Filters were then washed twice for 30 minutes each in 0.5x SSC, 0.1% SDS at 55°C and exposed to X-ray film overnight with an intensifying screen.
- Recombinant human GDNFR expression vectors may be prepared for expression in mammalian cells. As indicated above, expression may also be in non- mammalian cells, such as bacterial cells.
- the nucleic acid sequences disclosed herein may be placed into a commercially available mammalian vector (for example, CEP4, Invitrogen) for expression in mammalian cells, including the commercially available human embryonic kidney cell line, "293".
- a commercially available mammalian vector for example, CEP4, Invitrogen
- One may add an additional methionyl at the N- terminus for bacterial expression. Additionally, one may substitute the native leader sequence with a different leader sequence, or other sequence for cleavage for ease of expression.
- Soluble human GDNFR protein products were made.
- the following examples provide four different forms, differing only at the carboxy terminus, indicated by residue numbering as provided in Figure 2.
- Two are soluble forms truncated at different points just upstream from the hydrophobic tail and downstream from the last cysteine residue.
- the other two are the same truncations but with the addition of the "FLAG" sequence, an ⁇ ctapeptide to which a commercial antibody is available (Eastman Kodak).
- the FLAG sequence is H 2 N- DYKDDDDK - COOH.
- This fragment contained the hGDNFR- ⁇ - coding region from isoleucine-255 to glycine-443.
- Primers 4 and 5 were designed to produce fragments coding for the same regions of hGDNFR- ⁇ and primers 1 and 3, but with the addition of the Flag peptide coding sequence (IBI Kodak, New Haven, CN).
- the Flag peptide sequence consists of eight amino acids (H2N-Asp-Tyr-Lys-Asp-Asp-Asp-Lys-COOH) to which antibodies are commercially available.
- Primers 1 and 4 or 1 and 5 were used in PCR reactions with the same template as before, and digested with Hindlll and Bglll as before. This procedure produced fragments coding for isoleucine-255 to glycine-443 and isoleucine-255 to proline-446, but with the addition of the Flag peptide at their carboxy termini.
- Inserts from the pBKRSV clones were transferred to other expression vectors using enzyme sites present in the pBKRSV polylinker sequence as described below.
- Soluble GDNFRs e.g., sGDNFR- ⁇ /gly and sGDNFR- ⁇ /pro
- sGDNFR- ⁇ /gly and sGDNFR- ⁇ /pro have also been transferred into vectors for transient expression and into pDSR-2 for stable expression in CHO cells.
- the appropriate pBKRSV clone is digested with Xbal and Sail.
- the insert is ligated to pDSR ⁇ 2+PL cut with the same enzymes and treated with CIAP. This construction may be used for stable expression of GDNFR in CHO cells.
- the appropriate pBKRSV clone is digested with Spel and Xhol.
- the insert is ligated to pCEP4 (Invitrogen, San Diego, CA) digested with Nhel (Spel ends) and Xhol, and treated with CIAP. This construction may be used for transient of expression of GDNFR.
- the plasmid construct pDSR-2 is prepared substantially in accordance with the process described in the co-owned and copending U. S. Patent Application Serial Number 501 ,904 filed March 29, 1990 (also see, European Patent Application No. 90305433, Publication No. EP 398 753, filed May 18, 1990 and WO 90/14363 (1990), the disclosures of which are hereby incorporated by reference. It will be appreciated by those skilled in the art that a variety of nucleic acid sequences encoding GDNFR analogs may be used.
- Another construct is pDSR ⁇ 2, a derivative of the plasmid pCD (Okayama & Berg, Mol. Cell Biol.
- GDNFR- ⁇ in CHO cells has been verified by the binding of iodinated GDNF to the cell surface.
- the recombinantly expressed soluble GDNFR- ⁇ protein product may be used to potentiate the activity or cell specificity of GDNF.
- Soluble GDNFR- ⁇ attached to a detectable label also may be used in diagnostic applications as discussed above.
- GDNFR- ⁇ was transiently expressed on the surface of 293 T cells by transfection of the rat cDNA clone.
- Transfection of 293T cells was performed using the Calcium Phosphate Transfection System (GIBCO/BRL, Gaithersburg, MD) according to the manufacturers instructions. Two days following transfection, cells were removed by 2x versine treatment, washed once with washing buffer, and resuspended in washing buffer at a density of 2 x 10 ⁇ cells/mL. A duplicate set of cells were incubated with 0.5 u/mL PI-PLC at 37°C for 30 minutes before [ 125 I]GDNF binding.
- the cell suspension was divided into aliquots containing 1.5 x 10 ⁇ cell/sample. Cells were then pelleted and incubated with various concentrations of [ 125 I]GDNF in the presence or ahsence of 500 nM of unlabeled GDNF at 4°C for four hours with gentle agitation. Cells were washed four times with ice-cold washing buffer and resuspended in 0.5 mL washing buffer. Two 0.2 mL aliquots of the suspension were counted in a gamma counter to determine the amount of
- GDNFR- ⁇ transfected cells bound [ 12 *I]GDNF strongly even at picomolar concentrations. This binding was almost completely inhibited by 500 nM of unlabeled GDNF, indicating a specific binding of native GDNF to the expressed receptors.
- GDNFR- ⁇ expressed by the 293T cells can be released from the cells by treatment with phosphatidylinositol-specific phospholipase C (PI-PLC, Boehringer
- the major cross-linked species has a molecular mass consistent with a monomer of the receptor, a minor species with approximately the mass expected for a dimer has been found.
- Example 9 GDNF Signaling is Mediated by a Complex of GDNFR- ⁇ and the Ret Receptor Protein Tyrosine Kinase
- mice carrying targeted null mutations in the GDNF gene exhibit various defects in tissues derived from neural crest cells, in the autonomic nervous system, and in trigeminal and spinal cord motor neurons. The most severe defects are the absence of kidneys and complete loss of enteric neurons in digestive tract.
- the phenotype of GDNF knockout mice is strikingly similar to that of the c-ret knockout animals (Schuchardt et al. 1994), suggesting a possible linkage between the signal transduction pathways of GDNF and c-ret.
- the proto-oncogene c-ret was identified using probes derived from an oncogene isolated in gene transfer experiments (Takahashi et al., Cell. 42, 581-588, 1985; Takahashi and Cooper, Mol.
- Mutations in the c-ret gene are associated with inherited predisposition to cancer in familial medullary thyroid carcinoma (FMTC), and multiple endocrine neoplasia type 2A (MEN2A) and 2B (MEN2B). These diseases are probably caused by "gain of function" mutations that constitutively activate the Ret kinase (Donis- Keller et al., Hum. Molec. Genet. 2, 851-856, 1993; Hofstra et al., Nature. 367, 375-376, 1994; Mulligan et al., Nature. 363, 458-460, 1993; Santoro et al, Science. 267, 381-383, 1995). They confer a predisposition to malignancy specifically in tissues derived from the neural crest, where ret is normally expressed in early development. Another ret-associated genetic disorder, Hirschsprung's disease
- HSCR HSCR
- HSCR HSCR
- the most likely causes of HSCR are nonsense mutations that result in the production of truncated Ret protein lacking a kinase domain or missense mutations that inactivate the Ret kinase.
- targeted disruption of the c-ret proto- oncogene in mice results in renal agenesis or severe dysgenesis and lack of enteric neurons throughout the digestive tract (Schuchardt et al., 1994). This phenotype closely resembles that of GDNF knockout mice.
- GDNFR- ⁇ lacks a cytoplasmic domain, it must function through one or more accessory molecules in order to play a role in GDNF signal transduction.
- GDNF associates with the Ret protein tyrosine kinase receptor, and quickly induces Ret autophosphorylation.
- Neuro-2a Cells Expressing GDNFR- ⁇ Bind GDNF with High Affinity Neuro-2a is a mouse neuroblastoma cell line that endogenously expresses a high level of Ret protein (Ikeda et al., Oncogene. 5, 1291-1296, 1990; Iwamoto et al., Oncogene. 8, 1087-1091, 1993; Takahashi and Cooper, 1987) but does not express detectable levels of GDNFR- ⁇ mRNA as judged by Northern blot.
- Ret protein Ikeda et al., Oncogene. 5, 1291-1296, 1990; Iwamoto et al., Oncogene. 8, 1087-1091, 1993; Takahashi and Cooper, 1987
- a study was performed to examine the binding of [ 12 ⁇ I]GDNF to Neuro-2a cells engineered to express GDNFR- ⁇ .
- Neuro-2a cells were transfected with a mammalian expression vector containing the rat GDNFR- ⁇ cDNA (such as the expression plasmid described above).
- Three clonal lines, NGR-16, NGR-33, and NGR-38 were tested for their ability to bind [ 1 5 I]GDNF.
- the unbound [ 125 I]GDNF was removed at the end of the incubation and the amount of radioactivity associated with the cells was determined as described in Experimental Procedures. All three lines were able to bind [ 12 ⁇ I]GDNF specifically while parental Neuro-2a cells exhibited little or no [ 1 ⁇ I]GDNF binding ( Figure 6). Binding could be effectively competed by the addition of 500 nM unlabeled GDNF.
- Neuro-2a cells squares in the presence (open circles and open squares) or absence
- NGR-38 cells were incubated with [ 12 5l]GDNF, treated with cross-linking reagent, then lysed either directly in SDS-PAGE sample buffer or in Triton X-100 lysis buffer and further immunoprecipitated with anti-Ret antibody as described in the Experimental Procedures.
- the immunoprecipitates were analyzed by SDS-PAGE in the absence (NR) or presence (R) of - mercaptoethanol.
- Lysates were treated with Ret specific antibody, immunoprecipitated, and analyzed by SDS-PAGE under reducing conditions (see Figure 8, bands are marked as follows: -75 kD, solid triangle; ⁇ 150 kD, open triangle; -185 kD, solid arrow; -250 kD, asterisk; ⁇ 400kD, open arrow).
- the most prominent cross-linked species were at -75 kD, and -185 kD, with less intense bands of -150 kD and -250 kD.
- a very faint band of -400 kD was also visible ( Figure 8, lane 2).
- the -400 kD band was not reliably identified, partly due to the difficulty in estimating its molecular weight.
- the fact that it is prominent only under non- reducing conditions indicates that it is a disulfide-linked dimer of one or more of the species observed under reducing conditions.
- the most likely explanation is that it represents a dimer of the 185 kD species, although it may be a mixture of high molecular weight complexes consisting of two Ret, one or two GDNFR- ⁇ , and one or two GDNF molecules.
- the exact identity of the -250 kD band has not yet been determined.
- One possibility is that it represents cross-linked heterodimers of the -75 kD (GDNF + GDNFR- ⁇ ) and - 185 kD (GDNF + Ret) complexes.
- NGR-38 cells were treated with GDNF, lysed, and the lysates immunoprecipitated with anti-Ret antibody. The immunoprecipitates were analyzed by Western blot using an anti-phosphotyrosine antibody as described in the Experimental Procedures.
- Ret protein loaded in each lane as determined by reprobing of the immunoblot with anti-Ret antibody (Santa Cruz, C-19, Cat. #sc-167) is shown on the right side of panel A.
- the band at -150 kD represents an alternately glycosylated immature form of Ret that does not autophosphorylate.
- stimulation of Ret autophosphorylation in NGR-38 cells could be detected with 50 pg/mL of GDNF and the response was saturated at 20-50 ng/mL GDNF.
- the stimulation of Ret autophosphorylation by purified recombinant GDNF in NGR-38 cells over times of 0-20 minutes following treatment is shown in Figure 9C. Increased levels of Ret autophosphorylation could be observed within one minute of GDNF treatment and was maximal at 10 minutes following treatment (Figure 9C).
- GDNFR- ⁇ is anchored to the cytoplasmic membrane through a GPI linkage and can be released by treatment with phosphatidylinositol- specific phospholipase C (PI-PLC).
- PI-PLC phosphatidylinositol- specific phospholipase C
- Figure 10B depicts parental Neuro-2a cells treated with (lanes 2,4,6,8) or without (lanes 1,3,5,7) GDNF in the presence (lanes 5-8) or absence (lanes 1-4) of PI-PLC/CM obtained from Neuro-2a or NGR-38 cells, as analyzed for Ret autophosphorylation by immunoblotting as described in the Experimental Procedures.
- NGR-38 cells treated with GDNF were used as a positive control.
- the autophosphorylated 170 kD Ret bands are marked by solid arrows.
- Ret-Fc Fusion Protein Blocks Ret Phosphorylation Induced by GDNF and Soluble GDNFR- ⁇
- Ret-Fc Ret extracellular domain/Immunoglobulin Fc
- GDNF 50 ng/mL
- media containing soluble GDNFR- ⁇ e.g., PI-PLC/CM derived from NGR-38 cells
- Ret-Fc fusion protein either alone or in various combinations as indicated in Figure 11.
- Neuro-2a cells were treated with GDNF, media containing soluble GDNFR- ⁇ , Ret-Fc, or the pre-incubated mixtures. The cells were then lysed, and the lysates were analyzed for c-Ret autophosphorylation by immunoprecipitation using anti-Ret antibody as described in the Experimental Procedures. The immunoprecipitates were analyzed by Western blot using an anti-phosphotyrosine antibody.
- Receptors can be grouped into several classes based on their structure and mechanism of action. These classifications include the protein tyrosine kinases (PTKs), the serine/threonine kinases, and the cytokine receptors.
- PTKs protein tyrosine kinases
- cytokine receptors cytokine receptors.
- Receptor PTK signaling is initiated by a direct interaction with ligand, which induces receptor dimerization or oligomerization that in turn leads to receptor autophosphorylation.
- the activated receptor then recruits and phosphorylates intracellular substrates, initiating a cascade of events which culminates in a biological response (Schlessinger and Ullrich, Neuron 9, 383-391, 1992).
- signal transduction by serine/threonine kinase or cytokine receptors often involves formation of multi-component receptor complexes in which the ligand binding and signal transducing components are distinct.
- TGF- receptor complex a serine/threonine kinase receptor consisting of separate binding (Type II) and signaling (Type I) components and the CNTF family.
- CNTF, interleukin-6 (IL-6) and leukocyte inhibitory factor (LIF) share the common signaling components, gpl30 and/or LIFR, in their respective receptor complexes.
- CNTF receptor complex the ligand binding component is CNTF receptor (CNTFR), which like GDNFR, is a GPI-anchored membrane protein.
- CNTFR CNTF receptor
- the present invention involves the description of the first example of a receptor PTK whose autophosphorylation is dependent upon association with a separate ligand-specific binding component.
- GDNFR- ⁇ a GPI-linked membrane protein that binds to GDNF with high affinity, is required for the efficient association of GDNF with the Ret receptor PTK.
- GDNF is unable to bind to Ret or stimulate Ret receptor autophosphorylation.
- GDNFR- ⁇ GDNF associates with Ret and rapidly induces Ret autophosphorylation in a dose-dependent manner.
- GDNFR- ⁇ is able to function in either membrane bound or soluble forms ( Figure 11), as discussed above.
- GDNF concentrations of 50 pg/mL (1.7 pM) are able activate the Ret tyrosine kinase in cells expressing GDNFR- ⁇ .
- Ret can be activated by GDNF in cultured rat embryonic spinal cord motor neurons further demonstrates the biological relevance of the Ret/GDNF interaction. These cells are a primary target of GDNF in vivo, and have been shown to respond to low doses of GDNF in vitro (Henderson et al., 1994). Stimulation of Ret phosphorylation was abolished when the motor neuron cells were pre-treated with PI-PLC (data not shown), suggesting that the activation of Ret by GDNF requires GDNFR- ⁇ .
- FIG. 13 depicts a model for the binding of GDNF to GDNFR- ⁇ and Ret, and the consequent activation of the Ret PTK in response to GDNF.
- the initial event in this process is the binding of disulfide- linked dimeric GDNF to GDNFR- ⁇ in either monomeric or dimeric form.
- GDNF binding sites exist on these cells.
- Other cells such as embryonic chick sympathetic neurons, have been reported to bind GDNF with a Kd of 1-5 nM (Trupp et al, Journal Of Cell Biology. 130, 137-148, 1995). It is unlikely that GDNFR- ⁇ is involved in a receptor complex for such low affinity sites, but a weak direct interaction between GDNF and Ret may be present.
- c-ret has been observed during embryogenesis in many cell lineages of the developing central and peripheral nervous systems, including cells of the enteric nervous system (Pachnis, et al., Development, 119, 1005-1017, 1993; Tsuzuki et al., 1995). Outside the nervous system, c-ret expression has been detected in the Wolffian duct, ureteric bud epithelium and collecting ducts of the kidney (Pachnis, et al., supra; Tsuzuki et al., 1995).
- GDNF expression has also been detected in all neuroblastoma cell lines derived from the neural crest (Ikeda et al, 1990) and from surgically resected neuroblastomas (Nagao et al., 1990; Takahashi & Cooper, 1987).
- GDNF expression has been observed in both CNS and PNS, as well as in non-neuronal tissues during embryonic development. The levels of GDNF expression found in many non-neuronal tissues were higher than in the nervous system (Choi-Lundberg and Bohn, Brain Res. Dev. Brain Res. 85, 80-88, 1995).
- GDNFR- ⁇ Although expression of GDNFR- ⁇ has not been extensively studied, primary Northern blot analysis detected the presence of high levels of the GDNFR- ⁇ mRNA in the liver, brain, and kidney of adult rat and mouse. The similarity of the expression patterns of ret, GDNF, and GDNFR- ⁇ in developing nervous system and kidney is consistent with their combined action during development.
- Neuro-2a cells (ATCC #CCL 131) were transfected with an expression plasmid, as described above, using the Calcium Phosphate Transfection System (GIBCO/BRL) according to the manufacturer's directions. Transfected cells were selected for expression of the plasmid by growth in 400 ⁇ g/mL G418 antibiotic (Sigma). G418 resistant clones were expanded and assayed for GDNFR- ⁇ expression by binding to [ 2 ⁇ I]GDNF (Amersham, Inc., custom iodination, catalog #IMQ1057).
- G418 antibiotic Sigma
- Cells from each clone were seeded at a density of 3 x 10 4 cells/cm 2 in duplicate wells of 24- well tissue culture plates (Becton Dickinson) pre-coated with polyornithine. Cells were washed once with ice-cold washing buffer (DMEM containing 25 mM HEPES, pH 7.5) and were then incubated with 50 pM [ 125 I]GDNF in binding buffer (washing buffer plus 0.2% BSA) at 4°C for four hours either in the presence or absence of 500 mM unlabeled GDNF.
- DMEM containing 25 mM HEPES, pH 7.5
- GDNFR- ⁇ expressed by individual clones was estimated by the ratio of [ 12 ⁇ I]GDNF bound to cells in the absence and presence of unlabeled GDNF.
- Three clones were chosen as representatives of high, moderate, and low level expressors of GDNFR- ⁇ for use in binding experiments.
- the ratios [125jjGDNF bound in the absence and presence of unlabeled GDNF for these clones were: NGR-38) 16:1, NGR-16) 12.8:1, and NGR-33) 8:1.
- Neuro-2a or NGR-38 cells were washed once with phosphate-buffered saline (PBS, pH 7.1), then treated for four hours at 4°C with 1 or 3 nM [ 125 I]GDNF in binding buffer in the presence or absence of 500 nM unlabeled GDNF. Following binding, cells were washed four times with ice-cold washing buffer and incubated at room temperature for 45 minutes with 1 mM bis suberate (BS ⁇ , Pierce) in washing buffer. The cross-linking reaction was quenched by washing the cells three times with Tris-buffered saline (TBS, pH 7.5). The cells were then either lysed directly in SDS-PAGE sample buffer (80 mM Tris HC1 [pH 6.8], 10% glycerol, 1% SDS,
- Triton X-100 50 mM NaCl, 50 mM NaF, 10 mM sodium pyrophosphate, 1% aprotinin (Sigma, Cat.# A-6279), 1 mM PMSF (Sigma, Cat.# P-7626), 0.5 mM Na3VO4 (Fisher Cat.# S454-50).
- the lysates were clarified by centrifugation, incubated with 5 ⁇ g/mL of anti-Ret antibody (Santa Cruz Antibody, C-19, Cat. #SC-167), and the resulting immunocomplexes were collected by precipitation with protein A-Sepharose CL-4B (Pharmacia).
- the immunoprecipitates were washed three times with the lysis buffer, once with 0.5% NP-40 containing 50 mM NaCl and 20 mM Tris-Cl, pH 7.5, and were then resuspended in SDS-PAGE sample buffer. Both the whole cell lysates and the immunoprecipitates were fractionated by 7.5% SDS-PAGE with a ratio of Bis:Acrylamide at 1:200.
- Immunoprecipitates were fractionated by SDS-PAGE and transferred to nitrocellulose membranes as described by Harlow and Lane (Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, 1988).
- the membranes were pre-blocked with 5% BSA (Sigma) and the level of tyrosine phosphorylation of the receptor was determined by blotting the membrane with an anti-phosphotyrosine monoclonal antibody 4G10 (UBI, Cat. #05-321) at room temperature for two hours. The amount of protein included in each lane was determined by stripping and re-probing the same membrane with the anti-Ret antibody. Finally, the membrane was treated with chemiluminescence reagents (ECL, Amersham) following the manufacturer's instructions and exposed to X-ray films (Hyperfilm-ELC, Amersham).
- ECL chemiluminescence reagents
- PI-PLC phosphatidylinositol specific phospholipase C
- Boehringer Mannheim Cat. #1143069
- the cells were then washed three times with washing buffer and further processed for Ret autophosphorylation assay or cross- linking.
- PI-PLC treated conditioned media PI-PLC/CM
- 8 x 10 6 cells were removed from tissue culture dishes by treating the cells with PBS containing 2 mM of EDTA at 37°C for 5 to 10 minutes.
- Cells were washed once with washing buffer, resuspended in 1 mL of binding buffer containing 1 U/mL of PI-PLC, and incubated at 37°C for 45 minutes. The cells were pelleted, and the PI- PLC/CM was collected.
- a cDNA encompassing the entire coding region of c-Ret was isolated from a day 17 rat placenta cDNA library using an oligonucleotide probe corresponding to the first 20 amino acids of the mouse c-Ret (Iwamoto et al., 1993; van Heyningen, 1994).
- the region coding for the extracellular domain of the Ret receptor (ending with the last amino acid, R636) was fused in-frame with the DNA coding for the Fc region of human IgG (IgGl) and subcloned into the expression vector pDSR2 as previously described (Bartley et al., Nature. 368, 558-560, 1994).
- the ret- Fc/pDSRa2 plasmid was transfected into Chinese hamster ovary (CHO) cells and the recombinant Ret-Fc fusion protein was purified by affinity chromatography using a Ni ++ column (Qiagen).
- Embryonic Rat Spinal Cord Motor Neuron Cultures Enriched embryonic rat spinal cord motor neuron cultures were prepared from entire spinal cords of El 5 Sprague-Dawley rat fetuses 24 hours before the experiments. The spinal cords were dissected, and the meninges and dorsal root ganglia (DRGs) were removed. The spinal cords were cut into smaller fragments and digested with papain in Ll 5 medium (Papain Kit, Worthington). The motor neurons, which are larger than other types of cells included in the dissociated cell suspension, were enriched using a 6.8% Metrizamide gradient (Camu and Henderson, J Neuroscience. 44, 59-70, 1992).
- neurturin binds to both GDNFR- ⁇ and GRR2, a novel receptor related to GDNFR- ⁇ . Both GDNFR- ⁇ and GRR2 can mediate neurturin-induced autophosphorylation of the Ret protein tyrosine kinase.
- GDNF also binds both GDNFR- ⁇ and GRR2, and activates Ret in the presence of either binding receptor.
- neurturin binds GRR2 more effectively than GDNF, while GDNF binds GDNFR- ⁇ more efficiently than neurturin.
- neurturin a novel neurotrophic factor that is approximately 42% identical in amino acid sequence to GDNF.
- Both GDNF and neurturin are synthesized in pre- pro forms and their precursor molecules are proteolytically processed to yield mature proteins of about 100 amino acids that assemble into disulfide-linked homodimers. All seven cysteine residues crucial for the structure of GDNF and their spacing patterns are conserved in neurturin (Kotzbauer et al., 1996). Although the biological activities of neurturin have not yet been thoroughly investigated, they appear to be very similar to those of GDNF.
- neurturin and GDNF have been shown to promote the survival of sympathetic neurons derived from the superior cervical ganglia (SCG) and of sensory neurons of both the nodose (NG) and dorsal root ganglia (DRG).
- SCG superior cervical ganglia
- NG nodose
- DDG dorsal root ganglia
- Neurturin and GDNF mRNAs are widely distributed in a variety of both neuronal and non-neuronal tissues of embryos and adults. Both are found in brain, kidney, and lung, whereas neurturin mRNA is also expressed at high levels in neonatal blood.
- the structural and biological similarities between GDNF and neurturin suggest that their action may be mediated by the same or related receptors.
- the receptor for GDNF consists of a complex of GDNF receptor ⁇ (GDNFR- ⁇ ) and the Ret protein tyrosine kinase (PTK) (Jing et al., Cell, 85, 1113-1124, 1996; Treanor et al., Nature, 382, 80-83, 1996).
- GDNFR- ⁇ is a glycosyl-phosphodylinositol (GPI) anchored cell surface molecule that serves to bind GDNF but cannot signal independently since it lacks a cytoplasmic domain.
- GDNFR- ⁇ glycosyl-phosphodylinositol
- GDNFR- ⁇ mRNA is widely distributed in neuronal and nonneuronal tissues and is expressed through embryonic development to adulthood, implying a broad spectrum of biological functions (Treanor et al., 1996; Fox et al., unpublished data).
- the other component of the GDNF receptor complex, Ret is a receptor type PTK encoded by the ret proto-oncogene.
- Ret mRNA and protein are highly expressed in the CNS and PNS, as well as in the kidney.
- Various mutations in the ret gene are associated with inherited human diseases, including familial medullary thyroid carcinoma (FMTC), multiple endocrine neoplasia type 2A (MEN2A) and 2B (MEN2B), and Hirschsprung's disease.
- FMTC familial medullary thyroid carcinoma
- MEN2A multiple endocrine neoplasia type 2A
- MEN2B 2B
- Hirschsprung's disease including familial medullary thyroid carcinoma
- Targeted disruption of the ret gene in knockout mice results in severe phenotypic defects, including renal agenesis or severe dysgenesis and lack of entire enteric nervous system. These defects are extremely similar to those caused by GDNF null mutations, implying that GDNF- mediated signaling through Ret is required for the development of these tissues. Much less severe defects, however, were detected in a number of neuronal structures in which both GDNFR- ⁇ and Ret are expressed, such as the trigeminal and vestibular ganglia, the facial motor nucleos, the substantial nigra, and the locus coeruleus (Schuchardt et al., Nature, 367, 380-383, 1994; Treanor et al, 1996).
- GDNF signaling is not required for the embryonic development of these structures, or that some unknown signaling molecules similar to GDNF or Ret may exist that can substitute for them.
- the embryonic development of these tissues may completely rely on another yet unknown signaling system.
- This example describes the cloning of a novel GDNFR- ⁇ related receptor, GRR2, and provides evidence that GRR2 is a receptor for neurturin.
- GRR2 is a receptor for neurturin.
- neurturin effectively binds GRR2 and induces Ret activation.
- the data also show that both GDNF and neurturin can interact with either GDNFR- ⁇ or GRR2 and activate the Ret PTK in the presence of either binding receptor.
- EST human expressed sequence tag
- RT-PCR reverse transcription-polymerase chain reaction
- This clone contained a large open reading frame coding for a 464 amino acid protein related in sequence to GDNFR- ⁇ .
- GDNFR- ⁇ Related Receptor 2 GRR2
- the oligonucleotides described above were also used to screen pools from a rat photoreceptor cDNA library (Jing et al, 1996) by PCR and a product of the expected length was obtained from a single pool. An individual cDNA clone from this pool was identified by hybridization to the radiolabeled PCR product and sequenced.
- This clone contained a 2.2 kb insert with an open reading coding for a 460 amino acid peptide that is nearly identical to human GRR2.
- hGRR2 is 48%.
- the sequence is most divergent in the C-terminal region-amino acids 350-465 of hGDNFR- ⁇ are only 22% identical to amino acids 361-464 of hGRR2.
- hGDNFR- ⁇ and hGRR2 are more closely related, sharing 56% amino acid identity.
- the corresponding identities between the rat GDNFR- ⁇ and GRR2 are very similar: 48% overall, 26% in the C-terminal region, and 55% in the N-terminal region.
- the sequence comparison indicates that GDNFR- ⁇ and GRR2 are likely to be structurally very similar.
- amino acid sequences of human and rat GDNFR- ⁇ and GRR2 are aligned. Shaded areas indicate amino acids that are identical in all four sequences. Boxes indicate conservation between rat and human orthologs of the same receptor, but not between GDNFR- ⁇ and GRR2.
- LA-N-5 is a human neuroblastoma cell line (Sonnenfeld and Ishii, J. Neuroscience Research, 8:375-391, 1982) that expresses high levels of ret mRNA (Bunone et al., Exp. Cell. Res., 217:92-99, 1995). RT-PCR experiments using primers specific to GDNFR- ⁇ and GRR2 showed that these cells express GRR2 mRNA, but GDNFR- ⁇ mRNA was not detected (data not shown).
- NGR-38 is a cell line derived from mouse Neuro-2a cells (Jing et al., 1996).
- LA-N-5 and NGR-38 cells were incubated with [ 125 I]-labeled recombinant human neurturin (NTN) or GDNF in the absence or presence of excess unlabeled ligand.
- NTN human neurturin
- Figure 21 A [ 12 T]NTN bound to LA-N-5 cells more strongly than [ 125 I]GDNF, although both bound at detectable levels.
- the binding of [ 125 I]NTN to LA-N-5 cells was significantly inhibited by unlabeled neurturin, but not by GDNF.
- [ ,25 I]GDNF also bound to LA-N-5 cells, however, the binding was inhibited by either cold GDNF or neurturin.
- Figure 2 IB depicts the binding of [ 125 I]NTN and [ 125 I]GDNF to the GDNFR- ⁇ expressing cell line NGR-38. Although both [ 125 I]NTN and [ 125 I]GDNF bound to NGR-38 cells, [ 125 I]GDNF bound more strongly. As was observed for LA-N-5 cells, the binding of [ 125 I]GDNF to NGR-38 cells was inhibited by both unlabeled neurturin and GDNF, while binding of [ 125 I]NTN was only replaceable by neurturin (Figure 2 IB). Figure 21. Binding of Neurturin and GDNF to LA-N-5 and NGR-38 Cells
- LA-N-5 (A) and NGR-38 (B) cells were incubated with 50 pM of either [ 125 I]NTN or [ 125 I]GDNF in the absence (light gray bars) or presence of unlabeled GDNF (dark gray bars) or neurturin (black bars) at 4°C for 2 hours. The unbound ligands were removed at the end of the incubation and the radioactivity associated with the cells was determined as described.
- CM Conditioned medium
- Figure 22 Chemical Cross-Linking of Neurturin And GDNF to GDNFR- ⁇ and GRR2 Receptors.
- CM containing GDNFR- ⁇ /Fc (GDNFR- ⁇ ) or GRR2/Fc (GRR2) fusion proteins were incubated with either 10 nM of [ 125 I]NTN (N) or 5 nM of [ 125 I]GDNF (G) in the presence (+ unlabeled) or absence (- unlabeled) neurturin (N) or GDNF (G).
- the bound receptor-ligand complexes were chemically cross-linked by 1 mM of BS 3 , precipitated with Protein-A Sepharose and analyzed by SDS-PAGE as described.
- the solid arrow indicates the 90-110 kD and the 100-120 kD cross-linked species.
- the open arrow depicts the -280 kD and -300 kD complexes.
- neurturin may activate Ret through GDNFR- ⁇ .
- neurturin like GDNF, may activate Ret through GDNFR- ⁇ .
- the ability of neurturin to induce Ret autophosphorylation in NGR-38 cells was tested. NGR-38 cells were treated with concentrations of neurturin ranging from 0 to 50 nM, lysed, and the lysates immunoprecipitated with anti-Ret antibody. The immunoprecipitates were analyzed by SDS-PAGE followed by immunoblotting using an anti-phosphotyrosine antibody.
- FIG. 23 Neurturin and GDNF Induce Ret Autophosphorylation in NGR-38 Cells NGR-38 cells were treated with various concentrations of GDNF or neurturin as described. The cells were lysed, immunoprecipitated with anti-Ret antibody, fractionated by SDS-PAGE, and blotted with anti-phosphotyrosine antibody for Ret phosphorylation. The bands of phosphorylated Ret are indicated by an arrow.
- neurturin and GDNF bind to GRR2, and the Ret PTK can be activated by either neurturin or GDNF through GDNFR- ⁇ . These observations suggest that GRR2 may also be able to mediate neurturin and/or GDNF activation of Ret.
- human LA-N-5 neuroblastoma cells expressing GRR2 and Ret were treated with various concentrations of neurturin or GDNF and processed for immunoblotting as described in the previous section ( Figure 24). As shown, both neurturin and GDNF induced Ret autophosphorylation (Figure 24).
- FIG. 24 Neurturin And GDNF Induced Ret Autophosphorylation in LA-N-5 Cells
- LA-N-5 cells were treated with various concentrations of GDNF or neurturin as described.
- the cells were lysed, immunoprecipitated with anti-Ret antibody, fractionated by SDS-PAGE, and blotted with anti-phosphotyrosine antibody for Ret phosphorylation.
- the bands of phosphorylated Ret are indicated by an arrow.
- Treated cells were lysed directly in SDS-PAGE sample buffer, fractionated by SDS-PAGE, and immunoblotted using an anti-phosphorylated MAP kinase antibody (New England Biolabs, Beverly, MA). As shown in Figure 25, both p44 and p42 isoforms of MAP kinase are apparently activated by both neurturin and GDNF in either LA-N-5 or NGR-38 cells. MAP kinase activation by NGF (used as a positive control) was also observed.
- Figure 25 (Panels A and B). Neurturin And GDNF Induced MAP Kinase Activation in LA-N-5 And NGR-38 Cells
- LA-N-5 cells were treated with various concentrations of GDNF or neurturin as described. The cells were lysed directly in 2 X SDS-PAGE sample buffer containing 0.5 mM NaVO 4 , fractionated by SDS-PAGE, and blotted with an antibody against phosphorylated MAP kinase (MAPK-P). 25B. The membrane was stripped and reprobed with an anti-MAP kinase antibody for the amount of MAP kinase proteins loaded in each lane (MAPK). Discussion
- GDNFR- ⁇ an accessory molecule for ligand binding
- Ret receptor PTK transduces the GDNF signal.
- GDNF does not bind Ret alone, instead, it first binds to GDNFR- ⁇ and then interacts with Ret as a part of the GDNF-GDNFR- ⁇ complex.
- the newly cloned GRR2 is related to GDNFR- ⁇ at both the amino acid level and the three dimensional structure. It shares 48% identical amino acid residues with GDNFR- ⁇ , among which are 30 of the 31 cysteines.
- neurturin and GDNF bind to GDNFR- ⁇ and GRR2. Binding of GDNF or neurturin to either GDNFR- ⁇ or GRR2 results in further association of the ligand with Ret and consequent activation of the Ret PTK and the MAP kinase, a downstream signaling molecule. However, each of the ligands appears to bind to one receptor preferentially. Neurturin binds GRR2 expressing LA-N-5 cells more efficiently than GDNF, and GDNF binds GDNFR- ⁇ expressing NGR-38 cells more efficiently than neurturin.
- GDNF is more effectively cross-linked to GDNFR- ⁇ /Fc fusion receptors than to GRR2/Fc, while neurturin cross-linking shows the opposite result.
- the fragment was then radiolabeled with [ 32 P]-dCTP using a Random Primed DNA Labeling Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions.
- the radio-labeled probe was used to screen a human fetal brain cDNA library (Stratagene, La Jolla, CA). Two million clones were plated on 15 cm agarose plates and replicated on duplicate nitrocellulose filters. The filters were prehybridized at 55°C for 3.5 hours in 200 ml of 6 x SSC, 1 x Denhardts, 0.5% SDS, and 50 ⁇ g/ml salmon sperm DNA. Following the addition of 2 x 10 8 cpm of the radiolabeled probe, hybridization was continued for 18 hours. Filters were then washed twice for 30 minutes each at 55°C in 0.2 x SSC, 0.1% SDS and exposed to X-ray film overnight with an intensifying screen. Five positive clones were identified and their DNA sequences were determined.
- oligonucleotide primers described above were also used for PCR screening of DNAs isolated from 27 pools (1500 clones each) of a rat photoreceptor cDNA library (Jing et al., 1996). A single positive pool was identified and screened by hybridization to the same radio-labeled probe as described above. An individual cDNA clone from this pool was identified and sequenced.
- DNA sequencing was performed using an automated Applied Biosystems 373 A DNA sequencer and Taq DyeDeoxy Terminator cycle sequencing kits (Applied Biosystems, Foster City CA). Comparison of the GDNFR- ⁇ and GRR2 sequences with public databases was carried out using the FASTA computer algorithm (Pearson and Lipman, Proceedings Of The National Academy Of Sciences Of The United States Of America. 85, 2444-2448, 1988). The peptide sequences of GDNFR- ⁇ and GRR2 were aligned using the Lineup program. All sequence analysis programs used were included in the Wisconsin sequence analysis package (Wisconsin Package Version 9.0, Genetics Computer Group, Madison, WI).
- [ 2 _5l]NTN ( ⁇ 2000 Ci/mmole) was prepared using purified E. coli expressed protein (Amersham, Inc. , Arlington Heights, IL; custom iodination, catalog #IMQ1057). Recombinant human GDNF was also radio-iodinated (Jing et al,
- Binding of [ 125 I]NTN and [ 125 I]GDNF to LA-N-5 and NGR-38 cells were carried out as previously described (Jing et al., 1990). Briefly, cells were seeded one day before the assay in 24-well Costar tissue culture plates pre-coated with polyomithine at a density of 3 x 10 4 cells/cm 2 . Cells were placed on ice for 5 to 10 minutes, washed once with ice-cold buffer (DMEM containing 25 mM HEPES [pH
- [125j]QDNF in the absence or presence of 500 nM unlabeled ligands for 4 hours.
- Cells were washed 4 times with 0.5 ml ice-cold washing buffer and lysed with 0.5 ml of 1 M NaOH. The lysates were counted in a 1470 Wizard Automatic Gamma Counter (Wallac Inc., Gaithersburg, MD).
- GRR2/Fc fusion constructs were transfected into 293T cells, and conditioned media (CM, DMEM supplied with 0.5% fetal calf serum) containing the fusion proteins were collected 4 days after transfection. Aliquots of 1 ml CM plus 50 ⁇ l of 1 M HEPES, pH 7.5 were incubated at 4°C with 10 nM of [ 125 I]NTN or 5 nM [ 12 ⁇ I]GDNF in the presence or absence of 1 ⁇ M of unlabeled ligand for 4 hours. Bis suberate (BS ⁇ Pierce, Rockford, IL) stock solution in washing buffer (40 mM) was added to each binding mixture to a final concentration of 1 mM, mixed and incubated at room temperature for 30 minutes.
- CM conditioned media
- DMEM supplied with 0.5% fetal calf serum
- the reaction was quenched by adding 50 ⁇ l of 1 M glycine and incubating at room temperature for 15 minutes. Triton X-100 was added to a final concentration of 1%, and the cross-linked product was precipitated directly with 200 ⁇ l of Protein- A Sepharose CL-4B (Pharmacia). The cross-linked products were analyzed by 7.5% SDS-PAGE under reducing conditions.
- Ret autophosphorylation was examined by immunoblot analysis as previously described (Jing et al., 1996). Briefly, cells were seeded 24 hours prior to the assay in 6-well tissue culture dishes at a density of 1.5 x 10° " cells /well. Cells were washed once with binding buffer and treated with various concentrations of neurturin or GDNF (0.5 pM - 50 nM) in binding buffer at 37°C for 10 minutes.
- Treated cells and untreated controls were lysed in Triton X-100 lysis buffer (50 mM HEPES, pH 7.5, 1% Triton X-100, 50 mM NaCl, 50 mM NaF, 10 mM sodium pyrophosphate, 1% aprotinin (Sigma, Cat.# A-6279), 1 mM PMSF (Sigma, Cat.# P- 7626), 0.5 mM Na3VO4 (Fisher Cat.# S454-50) and immunoprecipitated with an anti-Ret antibody (Santa Cruz Biotechnology) and protein-A Sepharose as described (Jing et al., 1996). Immunoprecipitates were fractionated by 7.5% SDS-PAGE and transferred to nitrocellulose membranes as described by Harlow and Lane
- MAP kinases Activation of the MAP kinases was analyzed using a PhosphoPlus MAPK Antibody Kit (New England Biolabs, Beverly, MA, Cat. #9100) following manufacturer's instructions.
- LA-N-5 and NGR-38 cells were seeded in 6-well dishes as described above. Cells were quiesced in DMEM containing 0.5% fetal calf serum (FCS) at 37°C for 24 hours. The cells were then incubated with fresh media for 2 hours, treated with 50 ng/ml of NGF, GDNF, or neurturin at 37°C for 5 minutes, and lysed directly in 150 ⁇ l of 2 X SDS-PAGE sample buffer containing 0.5 mM NaVO4.
- FCS fetal calf serum
- the cell lysates were fractionated by 10% SDS-PAGE and transferred to a nitrocellulose filter.
- the filter was blocked with 5% non-fat dry milk at 4°C overnight and then incubated overnight at 4°C with a 1 : 1000 dilution of anti- phosphorylated MAP kinase antibody in the same buffer (New England Biolabs). Bands were detected using a horseradish peroxidase conjugated anti-rabbit antibody and the LumiGLO chemiluminescent reagents according to the manufacturer's recommendations. After exposure to X-ray film, the filter was stripped and reprobed by the anti-MAPK antibody .
- Figure 25 (Panels A and B). Neurturin And GDNF Induced MAP Kinase Activation in LA-N-5 And NGR-38 Cells
- LA-N-5 cells were treated with various concentrations of GDNF or neurturin as described. The cells were lysed directly in 2 X SDS-PAGE sample buffer containing 0.5 mM NaVO 4 , fractionated by SDS-PAGE, and blotted with an antibody against phosphorylated MAP kinase (MAPK-P). 25B. The membrane was stripped and reprobed with an anti-MAP kinase antibody for the amount of MAP kinase proteins loaded in each lane (MAPK).
- GDNFR- ⁇ GDNF receptor- ⁇
- GDNFR- ⁇ GDNF receptor- ⁇
- neurturin induces Ret activation through association with GRR2, a GDNFR- ⁇ -related receptor.
- GDNFR- ⁇ and GRR2 are capable of binding either GDNF or neurturin, but each exhibits a marked preference for its cognate ligand.
- a third molecule was cloned and is related in structure and primary amino acid sequence to GDNFR- ⁇ and GRR2.
- GDNFR- ⁇ -related receptor 3 This molecule has been named GDNFR- ⁇ -related receptor 3 (GRR3).
- GRR3 GDNFR- ⁇ -related receptor 3
- Analysis of the tissue distribution of GDNFR- ⁇ , GRR2, GRR3, and Ret by mRNA blot and in situ hybridization reveals overlapping but distinct patterns of expression. Consistent with their role in GDNF function, GDNFR- ⁇ and ret are co-expressed at known sites of GDNF action. GRR2 and GRR3 transcripts are also co-localized with those of ret in some cases, suggesting that GRR3 may also mediate Ret activation by GDNF or a related ligand.
- Glial cell line-derived neurotrophic factor is a potent survival factor for midbrain dopaminergic neurons, motor neurons, and several other types of neuronal cells.
- Targeted disruption of the GDNF gene in mice causes complete renal agenesis and the absence of enteric neurons (Moore et al., Nature, 382, 76-79, 1996; Pichel et al, Nature, 382, 73-76, 1996; Sanchez et al., Nature, 382, 70-73, 1996; and Hudson et al., Brain Research Bulletin, 36, 425-32, 1995), indicating an essential role for GDNF in the development of the renal and the enteric nervous systems.
- the GDNF receptor was discovered to consist of a novel ligand binding component, GDNFR- ⁇ , and a signaling component, the Ret receptor protein tyrosine kinase.
- GDNFR- ⁇ is attached to the cell membrane through a glycosyl- phosphatidylinositol (GPI) linkage but has no cytoplasmic domain. It binds GDNF specifically and with high affinity regardless of whether or not Ret is present.
- Ret is a receptor protein tyrosine kinase (PTK) originally discovered as a large open reading frame in the ret proto-oncogene.
- PTK receptor protein tyrosine kinase
- In situ hybridization and immunohistochemical analysis detects high level expression of ret mRNA and protein in the developing central and peripheral nervous systems and in the excretory system of the mouse embryo. This expression pattern is similar to that of GDNF and is consistent with Ret's role in GDNF signaling.
- GDNFR- ⁇ The expression pattern of GDNFR- ⁇ is also consistent with its involvement in GDNF signaling.
- GDNFR- ⁇ mRNA has been found in a number of GDNF- responsive cell types and structures of the nervous system, often colocalized with ret. In the central nervous system, GDNFR- ⁇ mRNA has been observed in both developing and adult rat ventral midbrain, facial nucleus and ventral spinal cord. In addition, some specific cells in the superior colliculus, the lateral septum, the molecular layer of cerebellum adjacent to Purkinje cells, and some nuclei in cerebral cortex and the dorsomedial tegmental area have been shown to express GDNFR- ⁇ .
- GDNFR- ⁇ mRNA expression has been found in subpopulations of neurons in dorsal root ganglia, in enteric neurons, and in neurons from sympathetic ganglia. High levels of GDNFR- ⁇ mRNA expression were also observed in other regions of the nervous system, including the retina, thalamus, pons, and medulla oblongata. Expression has also been seen in non-neuronal tissues such as the developing nephrons, pituitary, urogenital tract and pancreatic primordium. Neurturin is a molecule which has similarities to GDNF in both amino acid sequence and biological activity.
- the GRR2 protein (GDNFR- ⁇ -Related Receptor 2), is a novel protein related in amino acid sequence to GDNFR- ⁇ . GRR2 is capable of binding both GDNF and neurturin, and like GDNFR- ⁇ , mediates the activation of the Ret PTK in response to these ligands. Although both GDNF and neurturin can bind both GDNFR- ⁇ and GRR2, GDNF exhibits a marked preference for GDNFR- ⁇ while neurturin interacts more strongly with GRR2. GDNFR- ⁇ -Related Receptor 3 (GRR3) a third member of this receptor family has also been found. The present study examines the tissue and cell-specific mRNA expression of GDNFR- ⁇ , GRR2, GRR3, and ret.
- GDNFR- ⁇ -related receptor 3 GDNFR- ⁇ -related receptor 3
- FIG. 26 An alignment of the amino acid sequences of rat GDNFR- ⁇ , GRR2, and GRR3 is shown in Figure 26.
- the overall amino acid sequence identity among the three receptors is in the range of 30%-50%.
- GDNFR- ⁇ and GRR2 are somewhat more closely related to each other (48% identity) than they are to GRR3 (35% and 33%o identity, respectively).
- Hydrophobic regions are found at both the amino and carboxy termini of all three molecules, except for the amino terminus of GRR2 (underlined, Figure 26).
- the amino terminal regions of both GDNFR- ⁇ and GRR3 have the characteristics expected for signal peptide sequences. Although the GRR2 N-terminal sequence does not fit the criteria for a classical signal peptide, there is evidence that GRR2 is secreted.
- GDNFR- ⁇ The carboxy terminal hydrophobic region of GDNFR- ⁇ is known to be involved in GPI-linkage to the cell membrane, and it is likely that the corresponding regions in GRR2 and GRR3 serve the same purpose.
- the most striking feature of the sequence alignment is the conservation of 28 cysteine residues among all three receptors (highlighted, Figure 26), indicating that these proteins probably have similar three-dimensional structures.
- Several potential N-glycosylation sites are present in the receptors (shown in boldface, Figure 26), but none are found at the same position in all three receptors.
- GDNFR- ⁇ and GRR2 share sites at positions 365 and 427 that are not found in GRR3, and GRR2 shares a possible site with GRR3 at positions 322-323 ( Figure 26).
- GDNFR- ⁇ , GRR2 and GRR3 mRNAs were examined by blot hybridization analysis.
- GDNFR- ⁇ mRNA is widely expressed, with high levels found in lung, brain, liver, kidney and spleen. Expression is also detectable in heart and among the tissues examined is absent only in muscle and testis. Two distinct size transcripts are observed and their relative amounts vary among the tissues. The 3.6 kb transcript is predominant in liver, lung, heart, and spleen while comparable amounts of the 3.6 kb and 8.5 kb transcripts are present in brain and kidney.
- the tissue distribution of GRR2 mRNA is similar to that of GDNFR- ⁇ .
- GRR2 expression is highest in lung, spleen and brain, with lesser amounts in kidney and heart. One difference is the lack of GRR2 expression in liver.
- the size of the GRR2 transcripts is approximately 3.6 kb, similar to the smaller of the two GDNFR- ⁇ transcripts.
- the expression of GRR3 mRNA is highest in kidney and is absent in brain. Detectable expression of GRR3 is also present in spleen, lung, liver, and heart.
- the transcript size for GRR3 is somewhat smaller (-2.1 kb) than that observed for GDNFR- ⁇ and GRR2.
- GDNFR- ⁇ , GRR2, and GRR3 mRNA were examined in the mouse on embryonic days 7, 11, 15, and 17. Expression of the 3.6 kb transcript of GDNFR- ⁇ is first apparent at El 1, seems to decrease somewhat at El 5, but then increases dramatically by El 7. A minor amount of the 8.5 kb GDNFR- ⁇ mRNA can be detected on El 1, but no expression of this transcript is detected thereafter. The expression of the 3.6 kb GRR2 transcript is barely detectable at E 11 , but increases gradually through E 17. Expression of the 2.1 kb GRR3 mRNA is not detected at E7, but is quite strong by El 1. After El l, expression decreases and remains constant from E15-E17.
- GDNFR- ⁇ , GRR2 and GRR3, their expression was examined in regions where biological effects of GDNF have been demonstrated.
- GDNF is highly expressed in the growing ureteric buds and maturing nephrons of the kidney as well as in the enteric neurons of the intestine.
- GDNFR- ⁇ is found in the same regions of the kidney and intestine as GDNF, but is also expressed at moderate levels in both the dorsal and ventral spinal cord, ret is expressed in the kidney and intestine as well, although its expression in the kidney seems to be confined to the ureteric buds. Expression of ret is high in the ventral motor neurons, but low in the dorsal region of the spinal cord.
- GRR2 Like ret, expression of GRR2 in the kidney is restricted to the ureteric buds. GRR2 is expressed in both the dorsal and ventral regions of the spinal cord. A weak, diffuse hybridization signal was detected in the liver for GDNF, ret, and GDNFR- ⁇ . In the postnatal day 7 rat, ret expression can be detected at substantial levels in the substantia nigra, trigeminal ganglia, and at a lower level in the reticular thalamic nucleus. GDNFR- ⁇ expression is high in both the reticular and ventromedial thalamic nuclei as well as in the medial habenular nucleus.
- GRR2 is expressed at moderate levels in the reticular thalamic nucleus, ventromedial thalamic nucleus, cerebral cortex (especially the cingulate cortex), and the substantia nigra.
- GRR3 a novel molecule related to GDNFR- ⁇ and GRR2 and compares the tissue expression of ret with that of all three members of the GDNFR receptor family.
- GRR2 is 48% identical in amino acid sequence to GDNFR- ⁇ , while GRR3 is somewhat more distantly related at 35% identity. The position of 28 cysteine residues are conserved in all three molecules.
- GRR2 and GRR3 have hydrophobic C-termini that are likely to be involved in GPI linkage to the cell membrane, and neither has a cytoplasmic domain. This strong conservation of sequence and structural features suggests that GDNFR- ⁇ , GRR2, and GRR3 define a new family of receptors for GDNF and related ligands.
- GDNF signaling is initiated by binding to GDNFR- ⁇ and accomplished by association and consequent activation of the Ret PTK.
- GRR3 Based upon its sequence and structural similarities to GDNFR- ⁇ and GRR2, GRR3 is likely to function as a binding partner for GDNF, neurturin, and/or some other as yet undiscovered member of this ligand family.
- GDNFR- ⁇ , GRR2, and GRR3 The expression patterns of GDNFR- ⁇ , GRR2, and GRR3 in adult rat tissues are similar but distinct. All three mRNAs are found in lung, spleen, heart, and kidney while none of the three show significant expression in muscle or testis. Adult brain exhibits high expression of GDNFR- ⁇ and GRR2 mRNAs, but little or no GRR3 is detected. Expression of GDNFR- ⁇ mRNA is high in liver while GRR2 mRNA is almost nonexistent. If GDNF, neurturin and other as yet undiscovered GDNF-like ligands signal exclusively through Ret, differences in expression patterns of the ligand-specific binding receptors could provide a mechanism for ligand tissue specificity.
- GDNFR- ⁇ and GRR2 are transcribed along with ret in the kidney and intestine, in the substantia nigra, in the thalamus, and in ventral spinal motor neurons. This finding is consistent with GDNF's ability to promote the survival of dopaminergic and motor neurons and with the phenotypes of the Ret and GDNF knockout animals. Although little expression of GRR3 was found in the brain, it is co-expressed with ret and GDNFR- ⁇ in the trigeminal ganglia in El 8 and P7 rats. These observations indicate that GDNF action may be regulated by association with different binding components depending on the tissue and developmental stage, while always signaling through Ret.
- ret Although expression of ret is often co-localized with that of GDNFR- ⁇ , GRR2 and GRR3, there are several sites that express one or more of the binding receptors at high levels while ret expression is undetectable. Little or no ret is expressed in the spleen or lung where all three receptors are expressed at high levels. High levels of GDNFR- ⁇ mRNA are found in the liver, medial habenular nucleus, and the hippocampus, and GRR2 expression is prominent in the cortex. Little ret expression was observed in either of these regions. The lack of ret expression at some sites of substantial GDNFR expression suggests that either a signaling partner other than Ret may be employed by the GDNFRs in these tissues or that the receptors have an alternate mechanism of action. Two possibilities are that the receptors may act to sequester ligands of the GDNF family or that some fraction of the membrane bound receptors are released and mediate ligand function as soluble receptors.
- GenBank database was searched for sequences related to GDNFR- ⁇ and GRR2 using the Wisconsin sequence analysis package (Wisconsin Package Version 9.0, Genetics Computer Group, Madison, WI). Oligonucleotide primers corresponding to regions near the ends of the EST AA238748.Gb_New2 were synthesized. Primers corresponding to AA238748.Gb_New2 were used for PCR screening of 83 pools of 1000 clones each from a rat El 5 embryonic cDNA library. A single positive pool was identified by this method.
- the DNA fragment amplified from this pool was subcloned into a plasmid vector, and the insert was sequenced using an Applied Biosystems 373A automated DNA sequencer with Taq DyeDeoxy Terminator cycle sequencing kits (Applied Biosystems, Foster City, CA).
- the insert was then labeled with [ 32 P]-dCTP using a Random Primed DNA Labeling Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions.
- Clones from the cDNA library pool that had been identified as positive by PCR were plated on 15 cm agarose plates and replicated on duplicate nitrocellulose filters for screening by hybridization to the radiolabeled insert.
- Filters were prehybridized at 55°C for 3.5 hours in 200 ml of 6 x SSC, 1 x Denhardts, 0.5% SDS, and 50 ⁇ g/ml salmon sperm DNA. Following the addition of 2 x 10 8 cpm of the radiolabeled probe, hybridization was continued for 18 hours. Filters were then washed twice for 30 minutes each at 55°C in 0.2 x SSC, 0.1 % SDS and exposed to X-ray film overnight with an intensifying screen.
- RNA blot hybridization analysis For blot hybridization analysis, the cloned rat GRR3 cDNA was labeled using the Random Primed DNA Labeling Kit (Boehringer Mannheim, Indianapolis, IN) according to the manufacturer's instructions. Rat and mouse RNA blots (Clontech) were hybridized with the probe and washed at high stringency using the reagents of the ExpressHyb Kit (Clontech, Palo Alto, CA) according to the instructions of the manufacturer. Following exposure on X-ray film, the filters were stripped of probe by boiling in 0.5% SDS for 10 minutes and rehybridized with a ⁇ - actin probe (Clontech, Palo Alto, CA) as a control for total RNA loading.
- Rat and mouse RNA blots (Clontech) were hybridized with the probe and washed at high stringency using the reagents of the ExpressHyb Kit (Clontech, Palo Alto, CA) according to the instructions of the
- GRR2, and GRR3 was done according to Zhou et al. (Journal Of Neuroscience Research, 37, 129-143, 1994).
- the ret probe is a 316 nt fragment derived from the extracellular domain of the rat ret cDNA.
- GDNF mRNA was detected using a 303 nt fragment of a rat GDNF cDNA clone (nucleotide #50 to 352, Lin et al., 1993).
- GDNFR- ⁇ transcripts were detected with a 396 nt riboprobe (nucleotides 1072 to 1468).
- GRR2 transcripts were detected with a 205 nt antisense riboprobe corresponding to amino acids 339-413 ( Figure 26).
- GRR3 transcripts were detected with a 225 nt antisense riboprobe corresponding to amino acids 239-315 ( Figure 26).
- GDNF Prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15, 1465-1473.
- B61 is a Ligand for the ECK Receptor protein- tyrosine kinase. Nature. 368, 558-560.
- GDNF glial cell line-derived neurotrophic factor
- Glial cell line-derived neurotrophic factor stimulates fiber formation and survival in cultured neurons from peripheral autonomic ganglia. Journal Of Neuroscience Research. 40, 276-284.
- GDNF a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 266, 1062-1064.
- Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neuroscience Letters. 182, 107-111.
- CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gpl30. Cell. 69, 1121-1132.
- GDNF nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Research. 672, 104-111.
- GDNF a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260, 1130-1132.
- Glial cell line-derived neurotrophic factor promotes the survival and morphologic differentiation of Purkinje cells. Proceedings Of The National Academy Of Sciences Of The United States Of America. 92, 9092-9096.
- TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron. 13, 1245-1252.
- Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proceedings Of The National Academy Of Sciences Of The United States Of America. 92, 8935-8939.
- TGF-beta transforming growth factor beta
- Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo.
- Ret trasnforming gene encodes a fusion protein homologous to tyrosine kinases. Mol. Cell. Biol., 7, 1378-1385.
- SRa promoter an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8, 466-472.
- Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proceedings Of The National Academy Of Sciences Of The United States Of America. 92, 8274- 8278.
- GDNF Glial cell line-derived neurotrophic factor
- AGG CGA CAG ACC ATC GTG CCT GTG TGC TCC TAT GAA GAG AGG GAG AAG 1259 Arg Arg Gin Thr He Val Pro Val Cys Ser Tyr Glu Glu Arg Glu Lys 225 230 235 240
- AGG CGA CAG ACC ATC GTG CCT GTG TGC TCC TAT GAA GAG AGG GAG AAG 1259 Arg Arg Gin Thr He Val Pro Val Cys Ser Tyr Glu Glu Arg Glu Lys 225 230 235 240
- GTTCCATTCA ACTGGAACAT TTTTTTTTTTTTTT NCCTTTTAAG AAAGCTTCTT GTGATCCTTC 2107
- TCTAAGGTAA CTCCCATATC TCCTTTAATG ACATTGATTT CTAATGATAT AAATTTCAGC 2407 CTACATTGAT GCCAAGCTTT TTTGCCACAA AGAAGATTCT TACCAAGAGT GGGCTTTGTG 2467
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/866,354 US7138251B1 (en) | 1996-04-22 | 1997-05-30 | Polynucleotides encoding a neurotrophic factor receptor |
US866354 | 1997-05-30 | ||
PCT/US1998/008486 WO1998054213A2 (en) | 1997-05-30 | 1998-04-27 | Neurotrophic factor receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0983354A2 true EP0983354A2 (de) | 2000-03-08 |
Family
ID=25347430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98918805A Withdrawn EP0983354A2 (de) | 1997-05-30 | 1998-04-27 | Neurotrophen faktor rezeptoren |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0983354A2 (de) |
JP (1) | JP2002505576A (de) |
AU (1) | AU7165998A (de) |
CA (1) | CA2291608C (de) |
WO (1) | WO1998054213A2 (de) |
ZA (1) | ZA984404B (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696259B1 (en) | 1995-11-13 | 2004-02-24 | Licentia Ltd. | Assays using glial cell line-derived neurotrophic factor receptors |
US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
EP1007072A4 (de) * | 1997-05-22 | 2002-06-26 | Cephalon Inc | Rezeptoren neurotropher faktoren aus einer glia-zellinie |
US7026138B1 (en) | 1998-03-23 | 2006-04-11 | Genentech, Inc. | Polynucleotides encoding GFRα3 |
IL138593A0 (en) * | 1998-03-23 | 2001-10-31 | Genentech Inc | GFRα3 AND ITS USES |
DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
AU2017357931A1 (en) | 2016-11-10 | 2019-06-20 | Keros Therapeutics, Inc. | GDNF fusion polypeptides and methods of use thereof |
CN114555814A (zh) * | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | Aav相容的层粘连蛋白-连接子聚合蛋白 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4006054A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Verfahren zur immunologischen bestimmung von liganden |
EP1179350A3 (de) * | 1993-08-12 | 2003-01-02 | Cytotherapeutics, Inc. | Enkapsuliertes Zellsystem zur Implantation in dem menschlichen ZNC |
US6455277B1 (en) * | 1996-04-22 | 2002-09-24 | Amgen Inc. | Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
ES2270465T3 (es) * | 1996-05-08 | 2007-04-01 | Biogen Idec Ma Inc. | Ligando 3 ret para estimular el crecimiento neural y renal. |
EP0846764A3 (de) * | 1996-11-27 | 1998-09-30 | Smithkline Beecham Plc | Gliale neurotrophe Faktoren alpha Rezeptorfamilie |
JP4086324B2 (ja) * | 1997-02-18 | 2008-05-14 | ジェネンテク,インコーポレイテッド | ニュールツリン受容体 |
-
1998
- 1998-04-27 EP EP98918805A patent/EP0983354A2/de not_active Withdrawn
- 1998-04-27 CA CA002291608A patent/CA2291608C/en not_active Expired - Lifetime
- 1998-04-27 JP JP50067499A patent/JP2002505576A/ja not_active Ceased
- 1998-04-27 AU AU71659/98A patent/AU7165998A/en not_active Abandoned
- 1998-04-27 WO PCT/US1998/008486 patent/WO1998054213A2/en active Application Filing
- 1998-05-25 ZA ZA984404A patent/ZA984404B/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9854213A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2291608A1 (en) | 1998-12-03 |
WO1998054213A3 (en) | 1999-01-07 |
CA2291608C (en) | 2004-04-13 |
WO1998054213A2 (en) | 1998-12-03 |
JP2002505576A (ja) | 2002-02-19 |
AU7165998A (en) | 1998-12-30 |
ZA984404B (en) | 1998-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060166325A1 (en) | Glial cell line-derived neurotrophic factor receptor | |
US20030170822A1 (en) | Fibroblast growth factor-like molecules and uses thereof | |
US20110251267A1 (en) | Methods of using polynucleotides encoding truncated glial cell line-derived neurotrophic factor | |
CA2240516C (en) | Novel tyrosine kinase receptors and ligands | |
PL209952B1 (pl) | Wyizolowana cząsteczka kwasu nukleinowego, wyizolowany ludzki neurotroficzny czynnik wzrostu, plazmid, wektor ekspresyjny, komórka gospodarza, zastosowania cząsteczki kwasu nukleinowego, zastosowania neurotroficznego czynnika wzrostu, kompozycje faramaceutyczne, przeciwciało oraz sposób wykrywania neurotroficznego czynnika wzrostu | |
WO2000034475A9 (en) | Grnf4, a gdnf-related neurotrophic factor | |
US6413740B1 (en) | Tyrosine kinase receptors and ligands | |
EP0983354A2 (de) | Neurotrophen faktor rezeptoren | |
US7138251B1 (en) | Polynucleotides encoding a neurotrophic factor receptor | |
KR100399377B1 (ko) | Gdnf 단백질의 분석방법 및 검정 기구 | |
TW509696B (en) | Glial cell line-derived neurotrophic factor receptor | |
MXPA02005659A (es) | Moleculas similares a cordina y usos de las mismas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991125 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 19991125;LT PAYMENT 19991125;LV PAYMENT 19991125;MK PAYMENT 19991125;RO PAYMENT 19991125;SI PAYMENT 19991125 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AMGEN INC. |
|
17Q | First examination report despatched |
Effective date: 20030814 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090916 |